Canine Cancer: Strategies in Experimental Therapeutics
Identifieur interne : 000986 ( Pmc/Corpus ); précédent : 000985; suivant : 000987Canine Cancer: Strategies in Experimental Therapeutics
Auteurs : Douglas H. ThammSource :
- Frontiers in Oncology [ 2234-943X ] ; 2019.
Abstract
Cancer is the most common cause of death in adult dogs. Many features of spontaneously developing tumors in pet dogs contribute to their potential utility as a human disease model. These include similar environmental exposures, similar clonal evolution as it applies to important factors such as immune avoidance, a favorable body size for imaging and serial biopsy, and a relatively contracted time course of disease progression, which makes evaluation of temporal endpoints such as progression free or overall survival feasible in a comparatively short time frame. These criteria have been leveraged to evaluate novel local therapies, demonstrate proof of tumor target inhibition or tumor localization, evaluate potential antimetastatic approaches, and assess the efficacy, safety and immune effects of a variety of immune-based therapeutics. Some of these canine proof of concept studies have been instrumental in informing subsequent human clinical trials. This review will cover key aspects of clinical trials in dogs with spontaneous neoplasia, with examples of how these studies have contributed to human cancer therapeutic development.
Url:
DOI: 10.3389/fonc.2019.01257
PubMed: 31803625
PubMed Central: 6873901
Links to Exploration step
PMC:6873901Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Canine Cancer: Strategies in Experimental Therapeutics</title><author><name sortKey="Thamm, Douglas H" sort="Thamm, Douglas H" uniqKey="Thamm D" first="Douglas H." last="Thamm">Douglas H. Thamm</name><affiliation><nlm:aff id="aff1"><institution>Flint Animal Cancer Center, Colorado State University</institution>,<addr-line>Fort Collins, CO</addr-line>,<country>United States</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>Cell and Molecular Biology Graduate Program, Colorado State University</institution>,<addr-line>Fort Collins, CO</addr-line>,<country>United States</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff3"><institution>University of Colorado Cancer Center, Anschutz Medical Campus</institution>,<addr-line>Aurora, CO</addr-line>,<country>United States</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31803625</idno><idno type="pmc">6873901</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873901</idno><idno type="RBID">PMC:6873901</idno><idno type="doi">10.3389/fonc.2019.01257</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000986</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000986</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Canine Cancer: Strategies in Experimental Therapeutics</title><author><name sortKey="Thamm, Douglas H" sort="Thamm, Douglas H" uniqKey="Thamm D" first="Douglas H." last="Thamm">Douglas H. Thamm</name><affiliation><nlm:aff id="aff1"><institution>Flint Animal Cancer Center, Colorado State University</institution>,<addr-line>Fort Collins, CO</addr-line>,<country>United States</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff2"><institution>Cell and Molecular Biology Graduate Program, Colorado State University</institution>,<addr-line>Fort Collins, CO</addr-line>,<country>United States</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff3"><institution>University of Colorado Cancer Center, Anschutz Medical Campus</institution>,<addr-line>Aurora, CO</addr-line>,<country>United States</country></nlm:aff></affiliation></author></analytic><series><title level="j">Frontiers in Oncology</title><idno type="eISSN">2234-943X</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Cancer is the most common cause of death in adult dogs. Many features of spontaneously developing tumors in pet dogs contribute to their potential utility as a human disease model. These include similar environmental exposures, similar clonal evolution as it applies to important factors such as immune avoidance, a favorable body size for imaging and serial biopsy, and a relatively contracted time course of disease progression, which makes evaluation of temporal endpoints such as progression free or overall survival feasible in a comparatively short time frame. These criteria have been leveraged to evaluate novel local therapies, demonstrate proof of tumor target inhibition or tumor localization, evaluate potential antimetastatic approaches, and assess the efficacy, safety and immune effects of a variety of immune-based therapeutics. Some of these canine proof of concept studies have been instrumental in informing subsequent human clinical trials. This review will cover key aspects of clinical trials in dogs with spontaneous neoplasia, with examples of how these studies have contributed to human cancer therapeutic development.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Johnson, Ji" uniqKey="Johnson J">JI Johnson</name></author><author><name sortKey="Decker, S" uniqKey="Decker S">S Decker</name></author><author><name sortKey="Zaharevitz, D" uniqKey="Zaharevitz D">D Zaharevitz</name></author><author><name sortKey="Rubinstein, Lv" uniqKey="Rubinstein L">LV Rubinstein</name></author><author><name sortKey="Venditti, Jm" uniqKey="Venditti J">JM Venditti</name></author><author><name sortKey="Schepartz, S" uniqKey="Schepartz S">S Schepartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paoloni, M" uniqKey="Paoloni M">M Paoloni</name></author><author><name sortKey="Khanna, C" uniqKey="Khanna C">C Khanna</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fleming, Jm" uniqKey="Fleming J">JM Fleming</name></author><author><name sortKey="Creevy, Ke" uniqKey="Creevy K">KE Creevy</name></author><author><name sortKey="Promislow, De" uniqKey="Promislow D">DE Promislow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alvarez, Ce" uniqKey="Alvarez C">CE Alvarez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leblanc, Ak" uniqKey="Leblanc A">AK Leblanc</name></author><author><name sortKey="Mazcko, Cn" uniqKey="Mazcko C">CN Mazcko</name></author><author><name sortKey="Khanna, C" uniqKey="Khanna C">C Khanna</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leblanc, Ak" uniqKey="Leblanc A">AK Leblanc</name></author><author><name sortKey="Breen, M" uniqKey="Breen M">M Breen</name></author><author><name sortKey="Choyke, P" uniqKey="Choyke P">P Choyke</name></author><author><name sortKey="Dewhirst, M" uniqKey="Dewhirst M">M Dewhirst</name></author><author><name sortKey="Fan, Tm" uniqKey="Fan T">TM Fan</name></author><author><name sortKey="Gustafson, Dl" uniqKey="Gustafson D">DL Gustafson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ladue, T" uniqKey="Ladue T">T Ladue</name></author><author><name sortKey="Klein, Mk" uniqKey="Klein M">MK Klein</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="Michels, Gm" uniqKey="Michels G">GM Michels</name></author><author><name sortKey="Khanna, C" uniqKey="Khanna C">C Khanna</name></author><author><name sortKey="Selting, Ka" uniqKey="Selting K">KA Selting</name></author><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nguyen, Sm" uniqKey="Nguyen S">SM Nguyen</name></author><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cline, Jm" uniqKey="Cline J">JM Cline</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Page, Rl" uniqKey="Page R">RL Page</name></author><author><name sortKey="Franko, Aj" uniqKey="Franko A">AJ Franko</name></author><author><name sortKey="Raleigh, Ja" uniqKey="Raleigh J">JA Raleigh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeman, Em" uniqKey="Zeman E">EM Zeman</name></author><author><name sortKey="Calkins, Dp" uniqKey="Calkins D">DP Calkins</name></author><author><name sortKey="Cline, Jm" uniqKey="Cline J">JM Cline</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Raleigh, Ja" uniqKey="Raleigh J">JA Raleigh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cline, Jm" uniqKey="Cline J">JM Cline</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Rosner, Gl" uniqKey="Rosner G">GL Rosner</name></author><author><name sortKey="Raleigh, Ja" uniqKey="Raleigh J">JA Raleigh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raleigh, Ja" uniqKey="Raleigh J">JA Raleigh</name></author><author><name sortKey="Zeman, Em" uniqKey="Zeman E">EM Zeman</name></author><author><name sortKey="Calkins, Dp" uniqKey="Calkins D">DP Calkins</name></author><author><name sortKey="Mcentee, Mc" uniqKey="Mcentee M">MC Mcentee</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cline, Jm" uniqKey="Cline J">JM Cline</name></author><author><name sortKey="Rosner, Gl" uniqKey="Rosner G">GL Rosner</name></author><author><name sortKey="Raleigh, Ja" uniqKey="Raleigh J">JA Raleigh</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Rosner, Gl" uniqKey="Rosner G">GL Rosner</name></author><author><name sortKey="Azuma, C" uniqKey="Azuma C">C Azuma</name></author><author><name sortKey="Mcentee, Mc" uniqKey="Mcentee M">MC Mcentee</name></author><author><name sortKey="Raleigh, Ja" uniqKey="Raleigh J">JA Raleigh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zachos, Ta" uniqKey="Zachos T">TA Zachos</name></author><author><name sortKey="Aiken, Sw" uniqKey="Aiken S">SW Aiken</name></author><author><name sortKey="Diresta, Gr" uniqKey="Diresta G">GR Diresta</name></author><author><name sortKey="Healey, Jh" uniqKey="Healey J">JH Healey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Larue, Sm" uniqKey="Larue S">SM Larue</name></author><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Wrigley, Rh" uniqKey="Wrigley R">RH Wrigley</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Schwarz, Pd" uniqKey="Schwarz P">PD Schwarz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Straw, Rc" uniqKey="Straw R">RC Straw</name></author><author><name sortKey="Page, Rl" uniqKey="Page R">RL Page</name></author><author><name sortKey="Heidner, Gl" uniqKey="Heidner G">GL Heidner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Straw, Rc" uniqKey="Straw R">RC Straw</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Wrigley, Rh" uniqKey="Wrigley R">RH Wrigley</name></author><author><name sortKey="Larue, Sm" uniqKey="Larue S">SM Larue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author><author><name sortKey="Wilkins, Rm" uniqKey="Wilkins R">RM Wilkins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lascelles, Bd" uniqKey="Lascelles B">BD Lascelles</name></author><author><name sortKey="Dernell, Ws" uniqKey="Dernell W">WS Dernell</name></author><author><name sortKey="Correa, Mt" uniqKey="Correa M">MT Correa</name></author><author><name sortKey="Lafferty, M" uniqKey="Lafferty M">M Lafferty</name></author><author><name sortKey="Devitt, Cm" uniqKey="Devitt C">CM Devitt</name></author><author><name sortKey="Kuntz, Ca" uniqKey="Kuntz C">CA Kuntz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jeys, Lm" uniqKey="Jeys L">LM Jeys</name></author><author><name sortKey="Grimer, Rj" uniqKey="Grimer R">RJ Grimer</name></author><author><name sortKey="Carter, Sr" uniqKey="Carter S">SR Carter</name></author><author><name sortKey="Tillman, Rm" uniqKey="Tillman R">RM Tillman</name></author><author><name sortKey="Abudu, A" uniqKey="Abudu A">A Abudu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sottnik, Jl" uniqKey="Sottnik J">JL Sottnik</name></author><author><name sortKey="U Ren, Lw" uniqKey="U Ren L">LW U'Ren</name></author><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author><author><name sortKey="Dow, Sw" uniqKey="Dow S">SW Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Maurer, Gd" uniqKey="Maurer G">GD Maurer</name></author><author><name sortKey="Severin, Ga" uniqKey="Severin G">GA Severin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fike, Jr" uniqKey="Fike J">JR Fike</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Clow, Dj" uniqKey="Clow D">DJ Clow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gavin, Pr" uniqKey="Gavin P">PR Gavin</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Mcchesney, Sl" uniqKey="Mcchesney S">SL Mcchesney</name></author><author><name sortKey="Hoopes, Pj" uniqKey="Hoopes P">PJ Hoopes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoopes, Pj" uniqKey="Hoopes P">PJ Hoopes</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Benjamin, Sa" uniqKey="Benjamin S">SA Benjamin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Mcchesney, Sl" uniqKey="Mcchesney S">SL Mcchesney</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmadu Suka, F" uniqKey="Ahmadu Suka F">F Ahmadu-Suka</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author><author><name sortKey="Husted, Pw" uniqKey="Husted P">PW Husted</name></author><author><name sortKey="Nelson, Aw" uniqKey="Nelson A">AW Nelson</name></author><author><name sortKey="Whiteman, Ce" uniqKey="Whiteman C">CE Whiteman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ching, Sv" uniqKey="Ching S">SV Ching</name></author><author><name sortKey="Gillette, Sm" uniqKey="Gillette S">SM Gillette</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Roberts, Sm" uniqKey="Roberts S">SM Roberts</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gillette, Sm" uniqKey="Gillette S">SM Gillette</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Orton, Ec" uniqKey="Orton E">EC Orton</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Gillette, Sl" uniqKey="Gillette S">SL Gillette</name></author><author><name sortKey="Lecouteur, Ra" uniqKey="Lecouteur R">RA Lecouteur</name></author><author><name sortKey="Withrow, Sj" uniqKey="Withrow S">SJ Withrow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gillette, Sm" uniqKey="Gillette S">SM Gillette</name></author><author><name sortKey="Dewhirst, Mw" uniqKey="Dewhirst M">MW Dewhirst</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Page, Rl" uniqKey="Page R">RL Page</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcchesney, Sl" uniqKey="Mcchesney S">SL McChesney</name></author><author><name sortKey="Gillette, El" uniqKey="Gillette E">EL Gillette</name></author><author><name sortKey="Powers, Be" uniqKey="Powers B">BE Powers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mackie, Tr" uniqKey="Mackie T">TR Mackie</name></author><author><name sortKey="Kapatoes, J" uniqKey="Kapatoes J">J Kapatoes</name></author><author><name sortKey="Ruchala, K" uniqKey="Ruchala K">K Ruchala</name></author><author><name sortKey="Lu, W" uniqKey="Lu W">W Lu</name></author><author><name sortKey="Wu, C" uniqKey="Wu C">C Wu</name></author><author><name sortKey="Olivera, G" uniqKey="Olivera G">G Olivera</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Forrest, Lj" uniqKey="Forrest L">LJ Forrest</name></author><author><name sortKey="Mackie, Tr" uniqKey="Mackie T">TR Mackie</name></author><author><name sortKey="Ruchala, K" uniqKey="Ruchala K">K Ruchala</name></author><author><name sortKey="Turek, M" uniqKey="Turek M">M Turek</name></author><author><name sortKey="Kapatoes, J" uniqKey="Kapatoes J">J Kapatoes</name></author><author><name sortKey="Jaradat, H" uniqKey="Jaradat H">H Jaradat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Larue, Sm" uniqKey="Larue S">SM Larue</name></author><author><name sortKey="Pruitt, Af" uniqKey="Pruitt A">AF Pruitt</name></author><author><name sortKey="Case, B" uniqKey="Case B">B Case</name></author><author><name sortKey="Dewhirst, Mw" uniqKey="Dewhirst M">MW Dewhirst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chi, Jt" uniqKey="Chi J">JT Chi</name></author><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Jiang, C" uniqKey="Jiang C">C Jiang</name></author><author><name sortKey="Snyder, S" uniqKey="Snyder S">S Snyder</name></author><author><name sortKey="Fels, D" uniqKey="Fels D">D Fels</name></author><author><name sortKey="Landon, C" uniqKey="Landon C">C Landon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thrall, De" uniqKey="Thrall D">DE Thrall</name></author><author><name sortKey="Maccarini, P" uniqKey="Maccarini P">P Maccarini</name></author><author><name sortKey="Stauffer, P" uniqKey="Stauffer P">P Stauffer</name></author><author><name sortKey="Macfall, J" uniqKey="Macfall J">J Macfall</name></author><author><name sortKey="Hauck, M" uniqKey="Hauck M">M Hauck</name></author><author><name sortKey="Snyder, S" uniqKey="Snyder S">S Snyder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hershey, Ae" uniqKey="Hershey A">AE Hershey</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Forrest, Lj" uniqKey="Forrest L">LJ Forrest</name></author><author><name sortKey="Bohling, Ca" uniqKey="Bohling C">CA Bohling</name></author><author><name sortKey="Stonerook, M" uniqKey="Stonerook M">M Stonerook</name></author><author><name sortKey="Placke, Me" uniqKey="Placke M">ME Placke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rodriguez, Co" uniqKey="Rodriguez C">CO Rodriguez</name></author><author><name sortKey="Crabbs, Ta" uniqKey="Crabbs T">TA Crabbs</name></author><author><name sortKey="Wilson, Dw" uniqKey="Wilson D">DW Wilson</name></author><author><name sortKey="Cannan, Va" uniqKey="Cannan V">VA Cannan</name></author><author><name sortKey="Skorupski, Ka" uniqKey="Skorupski K">KA Skorupski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khanna, C" uniqKey="Khanna C">C Khanna</name></author><author><name sortKey="Anderson, Pm" uniqKey="Anderson P">PM Anderson</name></author><author><name sortKey="Hasz, De" uniqKey="Hasz D">DE Hasz</name></author><author><name sortKey="Katsanis, E" uniqKey="Katsanis E">E Katsanis</name></author><author><name sortKey="Neville, M" uniqKey="Neville M">M Neville</name></author><author><name sortKey="Klausner, Js" uniqKey="Klausner J">JS Klausner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roberts, Nj" uniqKey="Roberts N">NJ Roberts</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Janku, F" uniqKey="Janku F">F Janku</name></author><author><name sortKey="Collins, A" uniqKey="Collins A">A Collins</name></author><author><name sortKey="Bai, Ry" uniqKey="Bai R">RY Bai</name></author><author><name sortKey="Staedtke, V" uniqKey="Staedtke V">V Staedtke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dow, Sw" uniqKey="Dow S">SW Dow</name></author><author><name sortKey="Elmslie, Re" uniqKey="Elmslie R">RE Elmslie</name></author><author><name sortKey="Willson, Ap" uniqKey="Willson A">AP Willson</name></author><author><name sortKey="Roche, L" uniqKey="Roche L">L Roche</name></author><author><name sortKey="Gorman, C" uniqKey="Gorman C">C Gorman</name></author><author><name sortKey="Potter, Ta" uniqKey="Potter T">TA Potter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Macewen, Eg" uniqKey="Macewen E">EG Macewen</name></author><author><name sortKey="Feinmehl, R" uniqKey="Feinmehl R">R Feinmehl</name></author><author><name sortKey="Towell, Tl" uniqKey="Towell T">TL Towell</name></author><author><name sortKey="Longhofer, Sl" uniqKey="Longhofer S">SL Longhofer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Finocchiaro, Lm" uniqKey="Finocchiaro L">LM Finocchiaro</name></author><author><name sortKey="Villaverde, Ms" uniqKey="Villaverde M">MS Villaverde</name></author><author><name sortKey="Gil Cardeza, Ml" uniqKey="Gil Cardeza M">ML Gil-Cardeza</name></author><author><name sortKey="Riveros, Md" uniqKey="Riveros M">MD Riveros</name></author><author><name sortKey="Glikin, Gc" uniqKey="Glikin G">GC Glikin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Westberg, S" uniqKey="Westberg S">S Westberg</name></author><author><name sortKey="Sadeghi, A" uniqKey="Sadeghi A">A Sadeghi</name></author><author><name sortKey="Svensson, E" uniqKey="Svensson E">E Svensson</name></author><author><name sortKey="Segall, T" uniqKey="Segall T">T Segall</name></author><author><name sortKey="Dimopoulou, M" uniqKey="Dimopoulou M">M Dimopoulou</name></author><author><name sortKey="Korsgren, O" uniqKey="Korsgren O">O Korsgren</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Theon, Ap" uniqKey="Theon A">AP Theon</name></author><author><name sortKey="Madewell, Br" uniqKey="Madewell B">BR Madewell</name></author><author><name sortKey="Moore, As" uniqKey="Moore A">AS Moore</name></author><author><name sortKey="Stephens, C" uniqKey="Stephens C">C Stephens</name></author><author><name sortKey="Krag, Dn" uniqKey="Krag D">DN Krag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kitchell, Be" uniqKey="Kitchell B">BE Kitchell</name></author><author><name sortKey="Brown, Dm" uniqKey="Brown D">DM Brown</name></author><author><name sortKey="Luck, Ee" uniqKey="Luck E">EE Luck</name></author><author><name sortKey="Woods, Ll" uniqKey="Woods L">LL Woods</name></author><author><name sortKey="Orenberg, Ek" uniqKey="Orenberg E">EK Orenberg</name></author><author><name sortKey="Bloch, Da" uniqKey="Bloch D">DA Bloch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Theon, Ap" uniqKey="Theon A">AP Theon</name></author><author><name sortKey="Madewell, Br" uniqKey="Madewell B">BR Madewell</name></author><author><name sortKey="Ryu, J" uniqKey="Ryu J">J Ryu</name></author><author><name sortKey="Castro, J" uniqKey="Castro J">J Castro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kitchell, Bk" uniqKey="Kitchell B">BK Kitchell</name></author><author><name sortKey="Orenberg, Ek" uniqKey="Orenberg E">EK Orenberg</name></author><author><name sortKey="Brown, Dm" uniqKey="Brown D">DM Brown</name></author><author><name sortKey="Hutson, C" uniqKey="Hutson C">C Hutson</name></author><author><name sortKey="Ray, K" uniqKey="Ray K">K Ray</name></author><author><name sortKey="Woods, L" uniqKey="Woods L">L Woods</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Venable, Ro" uniqKey="Venable R">RO Venable</name></author><author><name sortKey="Worley, Dr" uniqKey="Worley D">DR Worley</name></author><author><name sortKey="Gustafson, Dl" uniqKey="Gustafson D">DL Gustafson</name></author><author><name sortKey="Hansen, Rj" uniqKey="Hansen R">RJ Hansen</name></author><author><name sortKey="Ehrhart, Ej" uniqKey="Ehrhart E">EJ Ehrhart</name></author><author><name sortKey="Cai, S" uniqKey="Cai S">S Cai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author><author><name sortKey="Galli, Sj" uniqKey="Galli S">SJ Galli</name></author><author><name sortKey="Yuuki, T" uniqKey="Yuuki T">T Yuuki</name></author><author><name sortKey="Hu, Zq" uniqKey="Hu Z">ZQ Hu</name></author><author><name sortKey="Helfand, Sc" uniqKey="Helfand S">SC Helfand</name></author><author><name sortKey="Geissler, En" uniqKey="Geissler E">EN Geissler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Decker, B" uniqKey="Decker B">B Decker</name></author><author><name sortKey="Parker, Hg" uniqKey="Parker H">HG Parker</name></author><author><name sortKey="Dhawan, D" uniqKey="Dhawan D">D Dhawan</name></author><author><name sortKey="Kwon, Em" uniqKey="Kwon E">EM Kwon</name></author><author><name sortKey="Karlins, E" uniqKey="Karlins E">E Karlins</name></author><author><name sortKey="Davis, Bw" uniqKey="Davis B">BW Davis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mochizuki, H" uniqKey="Mochizuki H">H Mochizuki</name></author><author><name sortKey="Breen, M" uniqKey="Breen M">M Breen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liao, At" uniqKey="Liao A">AT Liao</name></author><author><name sortKey="Chien, Mb" uniqKey="Chien M">MB Chien</name></author><author><name sortKey="Shenoy, N" uniqKey="Shenoy N">N Shenoy</name></author><author><name sortKey="Mendel, Db" uniqKey="Mendel D">DB Mendel</name></author><author><name sortKey="Mcmahon, G" uniqKey="Mcmahon G">G Mcmahon</name></author><author><name sortKey="Cherrington, Jm" uniqKey="Cherrington J">JM Cherrington</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author><author><name sortKey="Hannah, Al" uniqKey="Hannah A">AL Hannah</name></author><author><name sortKey="Zadovoskaya, R" uniqKey="Zadovoskaya R">R Zadovoskaya</name></author><author><name sortKey="Chien, Mb" uniqKey="Chien M">MB Chien</name></author><author><name sortKey="Kollias Baker, C" uniqKey="Kollias Baker C">C Kollias-Baker</name></author><author><name sortKey="Rosenberg, M" uniqKey="Rosenberg M">M Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pryer, Nk" uniqKey="Pryer N">NK Pryer</name></author><author><name sortKey="Lee, Lb" uniqKey="Lee L">LB Lee</name></author><author><name sortKey="Zadovaskaya, R" uniqKey="Zadovaskaya R">R Zadovaskaya</name></author><author><name sortKey="Yu, X" uniqKey="Yu X">X Yu</name></author><author><name sortKey="Sukbuntherng, J" uniqKey="Sukbuntherng J">J Sukbuntherng</name></author><author><name sortKey="Cherrington, Jm" uniqKey="Cherrington J">JM Cherrington</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author><author><name sortKey="Malpas, Pb" uniqKey="Malpas P">PB Malpas</name></author><author><name sortKey="Wood Follis, Sl" uniqKey="Wood Follis S">SL Wood-Follis</name></author><author><name sortKey="Boucher, Jf" uniqKey="Boucher J">JF Boucher</name></author><author><name sortKey="Rusk, Aw" uniqKey="Rusk A">AW Rusk</name></author><author><name sortKey="Rosenberg, Mp" uniqKey="Rosenberg M">MP Rosenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author><author><name sortKey="Bernabe, Lf" uniqKey="Bernabe L">LF Bernabe</name></author><author><name sortKey="Barnard, S" uniqKey="Barnard S">S Barnard</name></author><author><name sortKey="Kisseberth, Wc" uniqKey="Kisseberth W">WC Kisseberth</name></author><author><name sortKey="Borgatti, A" uniqKey="Borgatti A">A Borgatti</name></author><author><name sortKey="Henson, M" uniqKey="Henson M">M Henson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Honigberg, La" uniqKey="Honigberg L">LA Honigberg</name></author><author><name sortKey="Smith, Am" uniqKey="Smith A">AM Smith</name></author><author><name sortKey="Sirisawad, M" uniqKey="Sirisawad M">M Sirisawad</name></author><author><name sortKey="Verner, E" uniqKey="Verner E">E Verner</name></author><author><name sortKey="Loury, D" uniqKey="Loury D">D Loury</name></author><author><name sortKey="Chang, B" uniqKey="Chang B">B Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paoloni, Mc" uniqKey="Paoloni M">MC Paoloni</name></author><author><name sortKey="Tandle, A" uniqKey="Tandle A">A Tandle</name></author><author><name sortKey="Mazcko, C" uniqKey="Mazcko C">C Mazcko</name></author><author><name sortKey="Hanna, E" uniqKey="Hanna E">E Hanna</name></author><author><name sortKey="Kachala, S" uniqKey="Kachala S">S Kachala</name></author><author><name sortKey="Leblanc, A" uniqKey="Leblanc A">A Leblanc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="King, I" uniqKey="King I">I King</name></author><author><name sortKey="Li, Z" uniqKey="Li Z">Z Li</name></author><author><name sortKey="Sznol, M" uniqKey="Sznol M">M Sznol</name></author><author><name sortKey="Dubielzig, Rr" uniqKey="Dubielzig R">RR Dubielzig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Toso, Jf" uniqKey="Toso J">JF Toso</name></author><author><name sortKey="Gill, Vj" uniqKey="Gill V">VJ Gill</name></author><author><name sortKey="Hwu, P" uniqKey="Hwu P">P Hwu</name></author><author><name sortKey="Marincola, Fm" uniqKey="Marincola F">FM Marincola</name></author><author><name sortKey="Restifo, Np" uniqKey="Restifo N">NP Restifo</name></author><author><name sortKey="Schwartzentruber, Dj" uniqKey="Schwartzentruber D">DJ Schwartzentruber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hauck, Ml" uniqKey="Hauck M">ML Hauck</name></author><author><name sortKey="Larue, Sm" uniqKey="Larue S">SM Larue</name></author><author><name sortKey="Petros, Wp" uniqKey="Petros W">WP Petros</name></author><author><name sortKey="Poulson, Jm" uniqKey="Poulson J">JM Poulson</name></author><author><name sortKey="Yu, D" uniqKey="Yu D">D Yu</name></author><author><name sortKey="Spasojevic, I" uniqKey="Spasojevic I">I Spasojevic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnard, Ra" uniqKey="Barnard R">RA Barnard</name></author><author><name sortKey="Wittenburg, La" uniqKey="Wittenburg L">LA Wittenburg</name></author><author><name sortKey="Amaravadi, Rk" uniqKey="Amaravadi R">RK Amaravadi</name></author><author><name sortKey="Gustafson, Dl" uniqKey="Gustafson D">DL Gustafson</name></author><author><name sortKey="Thorburn, A" uniqKey="Thorburn A">A Thorburn</name></author><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burton, Jh" uniqKey="Burton J">JH Burton</name></author><author><name sortKey="Mazcko, C" uniqKey="Mazcko C">C Mazcko</name></author><author><name sortKey="Leblanc, A" uniqKey="Leblanc A">A Leblanc</name></author><author><name sortKey="Covey, Jm" uniqKey="Covey J">JM Covey</name></author><author><name sortKey="Ji, J" uniqKey="Ji J">J Ji</name></author><author><name sortKey="Kinders, Rj" uniqKey="Kinders R">RJ Kinders</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Macewen, Eg" uniqKey="Macewen E">EG Macewen</name></author><author><name sortKey="Rosenthal, Rc" uniqKey="Rosenthal R">RC Rosenthal</name></author><author><name sortKey="Fox, Le" uniqKey="Fox L">LE Fox</name></author><author><name sortKey="Keller, Et" uniqKey="Keller E">ET Keller</name></author><author><name sortKey="Helfand, Sc" uniqKey="Helfand S">SC Helfand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="Macewen, Eg" uniqKey="Macewen E">EG Macewen</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Dubielzig, Rr" uniqKey="Dubielzig R">RR Dubielzig</name></author><author><name sortKey="Helfand, Sc" uniqKey="Helfand S">SC Helfand</name></author><author><name sortKey="Kisseberth, Wc" uniqKey="Kisseberth W">WC Kisseberth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Shi, F" uniqKey="Shi F">F Shi</name></author><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="Macewen, Eg" uniqKey="Macewen E">EG Macewen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meyers, Pa" uniqKey="Meyers P">PA Meyers</name></author><author><name sortKey="Schwartz, Cl" uniqKey="Schwartz C">CL Schwartz</name></author><author><name sortKey="Krailo, M" uniqKey="Krailo M">M Krailo</name></author><author><name sortKey="Kleinerman, Es" uniqKey="Kleinerman E">ES Kleinerman</name></author><author><name sortKey="Betcher, D" uniqKey="Betcher D">D Betcher</name></author><author><name sortKey="Bernstein, Ml" uniqKey="Bernstein M">ML Bernstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Glawe, Pc" uniqKey="Glawe P">PC Glawe</name></author><author><name sortKey="O Brien, Mg" uniqKey="O Brien M">MG O'Brien</name></author><author><name sortKey="Chun, R" uniqKey="Chun R">R Chun</name></author><author><name sortKey="Garrett, Ld" uniqKey="Garrett L">LD Garrett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borgatti, A" uniqKey="Borgatti A">A Borgatti</name></author><author><name sortKey="Koopmeiners, Js" uniqKey="Koopmeiners J">JS Koopmeiners</name></author><author><name sortKey="Sarver, Al" uniqKey="Sarver A">AL Sarver</name></author><author><name sortKey="Winter, Al" uniqKey="Winter A">AL Winter</name></author><author><name sortKey="Stuebner, K" uniqKey="Stuebner K">K Stuebner</name></author><author><name sortKey="Todhunter, D" uniqKey="Todhunter D">D Todhunter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Itoh, H" uniqKey="Itoh H">H Itoh</name></author><author><name sortKey="Horiuchi, Y" uniqKey="Horiuchi Y">Y Horiuchi</name></author><author><name sortKey="Nagasaki, T" uniqKey="Nagasaki T">T Nagasaki</name></author><author><name sortKey="Sakonju, I" uniqKey="Sakonju I">I Sakonju</name></author><author><name sortKey="Kakuta, T" uniqKey="Kakuta T">T Kakuta</name></author><author><name sortKey="Fukushima, U" uniqKey="Fukushima U">U Fukushima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Andres, Pj" uniqKey="De Andres P">PJ De Andres</name></author><author><name sortKey="Illera, Jc" uniqKey="Illera J">JC Illera</name></author><author><name sortKey="Caceres, S" uniqKey="Caceres S">S Caceres</name></author><author><name sortKey="Diez, L" uniqKey="Diez L">L Diez</name></author><author><name sortKey="Perez Alenza, Md" uniqKey="Perez Alenza M">MD Perez-Alenza</name></author><author><name sortKey="Pena, L" uniqKey="Pena L">L Pena</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Jh" uniqKey="Kim J">JH Kim</name></author><author><name sortKey="Frantz, Am" uniqKey="Frantz A">AM Frantz</name></author><author><name sortKey="Anderson, Kl" uniqKey="Anderson K">KL Anderson</name></author><author><name sortKey="Graef, Aj" uniqKey="Graef A">AJ Graef</name></author><author><name sortKey="Scott, Mc" uniqKey="Scott M">MC Scott</name></author><author><name sortKey="Robinson, S" uniqKey="Robinson S">S Robinson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Troyer, Rm" uniqKey="Troyer R">RM Troyer</name></author><author><name sortKey="Ruby, Ce" uniqKey="Ruby C">CE Ruby</name></author><author><name sortKey="Goodall, Cp" uniqKey="Goodall C">CP Goodall</name></author><author><name sortKey="Yang, L" uniqKey="Yang L">L Yang</name></author><author><name sortKey="Maier, Cs" uniqKey="Maier C">CS Maier</name></author><author><name sortKey="Albarqi, Ha" uniqKey="Albarqi H">HA Albarqi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Biller, Bj" uniqKey="Biller B">BJ Biller</name></author><author><name sortKey="Elmslie, Re" uniqKey="Elmslie R">RE Elmslie</name></author><author><name sortKey="Burnett, Rc" uniqKey="Burnett R">RC Burnett</name></author><author><name sortKey="Avery, Ac" uniqKey="Avery A">AC Avery</name></author><author><name sortKey="Dow, Sw" uniqKey="Dow S">SW Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Neill, K" uniqKey="O Neill K">K O'Neill</name></author><author><name sortKey="Guth, A" uniqKey="Guth A">A Guth</name></author><author><name sortKey="Biller, B" uniqKey="Biller B">B Biller</name></author><author><name sortKey="Elmslie, R" uniqKey="Elmslie R">R Elmslie</name></author><author><name sortKey="Dow, S" uniqKey="Dow S">S Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Biller, Bj" uniqKey="Biller B">BJ Biller</name></author><author><name sortKey="Guth, A" uniqKey="Guth A">A Guth</name></author><author><name sortKey="Burton, Jh" uniqKey="Burton J">JH Burton</name></author><author><name sortKey="Dow, Sw" uniqKey="Dow S">SW Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goulart, Mr" uniqKey="Goulart M">MR Goulart</name></author><author><name sortKey="Pluhar, Ge" uniqKey="Pluhar G">GE Pluhar</name></author><author><name sortKey="Ohlfest, Jr" uniqKey="Ohlfest J">JR Ohlfest</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sherger, M" uniqKey="Sherger M">M Sherger</name></author><author><name sortKey="Kisseberth, W" uniqKey="Kisseberth W">W Kisseberth</name></author><author><name sortKey="London, C" uniqKey="London C">C London</name></author><author><name sortKey="Olivo Marston, S" uniqKey="Olivo Marston S">S Olivo-Marston</name></author><author><name sortKey="Papenfuss, Tl" uniqKey="Papenfuss T">TL Papenfuss</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goulart, Mr" uniqKey="Goulart M">MR Goulart</name></author><author><name sortKey="Hlavaty, Si" uniqKey="Hlavaty S">SI Hlavaty</name></author><author><name sortKey="Chang, Ym" uniqKey="Chang Y">YM Chang</name></author><author><name sortKey="Polton, G" uniqKey="Polton G">G Polton</name></author><author><name sortKey="Stell, A" uniqKey="Stell A">A Stell</name></author><author><name sortKey="Perry, J" uniqKey="Perry J">J Perry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beirao, Bc" uniqKey="Beirao B">BC Beirao</name></author><author><name sortKey="Raposo, T" uniqKey="Raposo T">T Raposo</name></author><author><name sortKey="Pang, Ly" uniqKey="Pang L">LY Pang</name></author><author><name sortKey="Argyle, Dj" uniqKey="Argyle D">DJ Argyle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Regan, Dp" uniqKey="Regan D">DP Regan</name></author><author><name sortKey="Escaffi, A" uniqKey="Escaffi A">A Escaffi</name></author><author><name sortKey="Coy, J" uniqKey="Coy J">J Coy</name></author><author><name sortKey="Kurihara, J" uniqKey="Kurihara J">J Kurihara</name></author><author><name sortKey="Dow, Sw" uniqKey="Dow S">SW Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Monteiro, Ln" uniqKey="Monteiro L">LN Monteiro</name></author><author><name sortKey="Rodrigues, Ma" uniqKey="Rodrigues M">MA Rodrigues</name></author><author><name sortKey="Gomes, Da" uniqKey="Gomes D">DA Gomes</name></author><author><name sortKey="Salgado, Bs" uniqKey="Salgado B">BS Salgado</name></author><author><name sortKey="Cassali, Gd" uniqKey="Cassali G">GD Cassali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seung, Bj" uniqKey="Seung B">BJ Seung</name></author><author><name sortKey="Lim, Hy" uniqKey="Lim H">HY Lim</name></author><author><name sortKey="Shin, Ji" uniqKey="Shin J">JI Shin</name></author><author><name sortKey="Kim, Hw" uniqKey="Kim H">HW Kim</name></author><author><name sortKey="Cho, Sh" uniqKey="Cho S">SH Cho</name></author><author><name sortKey="Kim, Sh" uniqKey="Kim S">SH Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maekawa, N" uniqKey="Maekawa N">N Maekawa</name></author><author><name sortKey="Konnai, S" uniqKey="Konnai S">S Konnai</name></author><author><name sortKey="Ikebuchi, R" uniqKey="Ikebuchi R">R Ikebuchi</name></author><author><name sortKey="Okagawa, T" uniqKey="Okagawa T">T Okagawa</name></author><author><name sortKey="Adachi, M" uniqKey="Adachi M">M Adachi</name></author><author><name sortKey="Takagi, S" uniqKey="Takagi S">S Takagi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maekawa, N" uniqKey="Maekawa N">N Maekawa</name></author><author><name sortKey="Konnai, S" uniqKey="Konnai S">S Konnai</name></author><author><name sortKey="Okagawa, T" uniqKey="Okagawa T">T Okagawa</name></author><author><name sortKey="Nishimori, A" uniqKey="Nishimori A">A Nishimori</name></author><author><name sortKey="Ikebuchi, R" uniqKey="Ikebuchi R">R Ikebuchi</name></author><author><name sortKey="Izumi, Y" uniqKey="Izumi Y">Y Izumi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ambrosius, La" uniqKey="Ambrosius L">LA Ambrosius</name></author><author><name sortKey="Dhawan, D" uniqKey="Dhawan D">D Dhawan</name></author><author><name sortKey="Ramos Vara, Ja" uniqKey="Ramos Vara J">JA Ramos-Vara</name></author><author><name sortKey="Ruple, A" uniqKey="Ruple A">A Ruple</name></author><author><name sortKey="Knapp, Dw" uniqKey="Knapp D">DW Knapp</name></author><author><name sortKey="Childress, Mo" uniqKey="Childress M">MO Childress</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hartley, G" uniqKey="Hartley G">G Hartley</name></author><author><name sortKey="Elmslie, R" uniqKey="Elmslie R">R Elmslie</name></author><author><name sortKey="Dow, S" uniqKey="Dow S">S Dow</name></author><author><name sortKey="Guth, A" uniqKey="Guth A">A Guth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chand, Sk" uniqKey="Chand S">SK Chand</name></author><author><name sortKey="Pendharkar, Sa" uniqKey="Pendharkar S">SA Pendharkar</name></author><author><name sortKey="Bharmal, Sh" uniqKey="Bharmal S">SH Bharmal</name></author><author><name sortKey="Bartlett, As" uniqKey="Bartlett A">AS Bartlett</name></author><author><name sortKey="Pandol, Sj" uniqKey="Pandol S">SJ Pandol</name></author><author><name sortKey="Petrov, Ms" uniqKey="Petrov M">MS Petrov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bech Nielsen, S" uniqKey="Bech Nielsen S">S Bech-Nielsen</name></author><author><name sortKey="Brodey, Rs" uniqKey="Brodey R">RS Brodey</name></author><author><name sortKey="Fidler, Ij" uniqKey="Fidler I">IJ Fidler</name></author><author><name sortKey="Abt, Da" uniqKey="Abt D">DA Abt</name></author><author><name sortKey="Reif, Js" uniqKey="Reif J">JS Reif</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bostock, De" uniqKey="Bostock D">DE Bostock</name></author><author><name sortKey="Gorman, Nt" uniqKey="Gorman N">NT Gorman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meyer, Ja" uniqKey="Meyer J">JA Meyer</name></author><author><name sortKey="Dueland, Rt" uniqKey="Dueland R">RT Dueland</name></author><author><name sortKey="Macewen, Eg" uniqKey="Macewen E">EG Macewen</name></author><author><name sortKey="Macy, Dw" uniqKey="Macy D">DW Macy</name></author><author><name sortKey="Hoefle, Wd" uniqKey="Hoefle W">WD Hoefle</name></author><author><name sortKey="Richardson, Rc" uniqKey="Richardson R">RC Richardson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parodi, Al" uniqKey="Parodi A">AL Parodi</name></author><author><name sortKey="Misdorp, W" uniqKey="Misdorp W">W Misdorp</name></author><author><name sortKey="Mialot, Jp" uniqKey="Mialot J">JP Mialot</name></author><author><name sortKey="Mialot, M" uniqKey="Mialot M">M Mialot</name></author><author><name sortKey="Hart, Aa" uniqKey="Hart A">AA Hart</name></author><author><name sortKey="Hurtrel, M" uniqKey="Hurtrel M">M Hurtrel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henry, Cj" uniqKey="Henry C">CJ Henry</name></author><author><name sortKey="Downing, S" uniqKey="Downing S">S Downing</name></author><author><name sortKey="Rosenthal, Rc" uniqKey="Rosenthal R">RC Rosenthal</name></author><author><name sortKey="Klein, Mk" uniqKey="Klein M">MK Klein</name></author><author><name sortKey="Meleo, K" uniqKey="Meleo K">K Meleo</name></author><author><name sortKey="Villamil, Ja" uniqKey="Villamil J">JA Villamil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Macewen, Eg" uniqKey="Macewen E">EG Macewen</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Vail, Dm" uniqKey="Vail D">DM Vail</name></author><author><name sortKey="Dubielzig, Rr" uniqKey="Dubielzig R">RR Dubielzig</name></author><author><name sortKey="Everlith, K" uniqKey="Everlith K">K Everlith</name></author><author><name sortKey="Madewell, Br" uniqKey="Madewell B">BR Madewell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moore, As" uniqKey="Moore A">AS Moore</name></author><author><name sortKey="Theilen, Gh" uniqKey="Theilen G">GH Theilen</name></author><author><name sortKey="Newell, Ad" uniqKey="Newell A">AD Newell</name></author><author><name sortKey="Madewell, Br" uniqKey="Madewell B">BR Madewell</name></author><author><name sortKey="Rudolf, Ar" uniqKey="Rudolf A">AR Rudolf</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mito, K" uniqKey="Mito K">K Mito</name></author><author><name sortKey="Sugiura, K" uniqKey="Sugiura K">K Sugiura</name></author><author><name sortKey="Ueda, K" uniqKey="Ueda K">K Ueda</name></author><author><name sortKey="Hori, T" uniqKey="Hori T">T Hori</name></author><author><name sortKey="Akazawa, T" uniqKey="Akazawa T">T Akazawa</name></author><author><name sortKey="Yamate, J" uniqKey="Yamate J">J Yamate</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Henson, Ms" uniqKey="Henson M">MS Henson</name></author><author><name sortKey="Curtsinger, Jm" uniqKey="Curtsinger J">JM Curtsinger</name></author><author><name sortKey="Larson, Vs" uniqKey="Larson V">VS Larson</name></author><author><name sortKey="Klausner, Js" uniqKey="Klausner J">JS Klausner</name></author><author><name sortKey="Modiano, Jf" uniqKey="Modiano J">JF Modiano</name></author><author><name sortKey="Mescher, Mf" uniqKey="Mescher M">MF Mescher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Konietschke, U" uniqKey="Konietschke U">U Konietschke</name></author><author><name sortKey="Teske, E" uniqKey="Teske E">E Teske</name></author><author><name sortKey="Jurina, K" uniqKey="Jurina K">K Jurina</name></author><author><name sortKey="Stockhaus, C" uniqKey="Stockhaus C">C Stockhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haagsman, An" uniqKey="Haagsman A">AN Haagsman</name></author><author><name sortKey="Witkamp, Ac" uniqKey="Witkamp A">AC Witkamp</name></author><author><name sortKey="Sjollema, Be" uniqKey="Sjollema B">BE Sjollema</name></author><author><name sortKey="Kik, Mj" uniqKey="Kik M">MJ Kik</name></author><author><name sortKey="Kirpensteijn, J" uniqKey="Kirpensteijn J">J Kirpensteijn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ziekman, Pg" uniqKey="Ziekman P">PG Ziekman</name></author><author><name sortKey="Otter, Wd" uniqKey="Otter W">WD Otter</name></author><author><name sortKey="Tan, Jf" uniqKey="Tan J">JF Tan</name></author><author><name sortKey="Teske, E" uniqKey="Teske E">E Teske</name></author><author><name sortKey="Kirpensteijn, J" uniqKey="Kirpensteijn J">J Kirpensteijn</name></author><author><name sortKey="Koten, Jw" uniqKey="Koten J">JW Koten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Finocchiaro, Lm" uniqKey="Finocchiaro L">LM Finocchiaro</name></author><author><name sortKey="Fondello, C" uniqKey="Fondello C">C Fondello</name></author><author><name sortKey="Gil Cardeza, Ml" uniqKey="Gil Cardeza M">ML Gil-Cardeza</name></author><author><name sortKey="Rossi, Ua" uniqKey="Rossi U">UA Rossi</name></author><author><name sortKey="Villaverde, Ms" uniqKey="Villaverde M">MS Villaverde</name></author><author><name sortKey="Riveros, Md" uniqKey="Riveros M">MD Riveros</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Monjazeb, Am" uniqKey="Monjazeb A">AM Monjazeb</name></author><author><name sortKey="Kent, Ms" uniqKey="Kent M">MS Kent</name></author><author><name sortKey="Grossenbacher, Sk" uniqKey="Grossenbacher S">SK Grossenbacher</name></author><author><name sortKey="Mall, C" uniqKey="Mall C">C Mall</name></author><author><name sortKey="Zamora, Ae" uniqKey="Zamora A">AE Zamora</name></author><author><name sortKey="Mirsoian, A" uniqKey="Mirsoian A">A Mirsoian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cicchelero, L" uniqKey="Cicchelero L">L Cicchelero</name></author><author><name sortKey="Denies, S" uniqKey="Denies S">S Denies</name></author><author><name sortKey="Haers, H" uniqKey="Haers H">H Haers</name></author><author><name sortKey="Vanderperren, K" uniqKey="Vanderperren K">K Vanderperren</name></author><author><name sortKey="Stock, E" uniqKey="Stock E">E Stock</name></author><author><name sortKey="Van Brantegem, L" uniqKey="Van Brantegem L">L Van Brantegem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paoloni, M" uniqKey="Paoloni M">M Paoloni</name></author><author><name sortKey="Mazcko, C" uniqKey="Mazcko C">C Mazcko</name></author><author><name sortKey="Selting, K" uniqKey="Selting K">K Selting</name></author><author><name sortKey="Lana, S" uniqKey="Lana S">S Lana</name></author><author><name sortKey="Barber, L" uniqKey="Barber L">L Barber</name></author><author><name sortKey="Phillips, J" uniqKey="Phillips J">J Phillips</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="London, Ca" uniqKey="London C">CA London</name></author><author><name sortKey="Gardner, Hl" uniqKey="Gardner H">HL Gardner</name></author><author><name sortKey="Rippy, S" uniqKey="Rippy S">S Rippy</name></author><author><name sortKey="Post, G" uniqKey="Post G">G Post</name></author><author><name sortKey="La Perle, K" uniqKey="La Perle K">K La Perle</name></author><author><name sortKey="Crew, L" uniqKey="Crew L">L Crew</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maekawa, N" uniqKey="Maekawa N">N Maekawa</name></author><author><name sortKey="Konnai, S" uniqKey="Konnai S">S Konnai</name></author><author><name sortKey="Takagi, S" uniqKey="Takagi S">S Takagi</name></author><author><name sortKey="Kagawa, Y" uniqKey="Kagawa Y">Y Kagawa</name></author><author><name sortKey="Okagawa, T" uniqKey="Okagawa T">T Okagawa</name></author><author><name sortKey="Nishimori, A" uniqKey="Nishimori A">A Nishimori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hogge, Gs" uniqKey="Hogge G">GS Hogge</name></author><author><name sortKey="Burkholder, Jk" uniqKey="Burkholder J">JK Burkholder</name></author><author><name sortKey="Culp, J" uniqKey="Culp J">J Culp</name></author><author><name sortKey="Albertini, Mr" uniqKey="Albertini M">MR Albertini</name></author><author><name sortKey="Dubielzig, Rr" uniqKey="Dubielzig R">RR Dubielzig</name></author><author><name sortKey="Keller, Et" uniqKey="Keller E">ET Keller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Turek, Mm" uniqKey="Turek M">MM Turek</name></author><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author><author><name sortKey="Mitzey, A" uniqKey="Mitzey A">A Mitzey</name></author><author><name sortKey="Kurzman, Id" uniqKey="Kurzman I">ID Kurzman</name></author><author><name sortKey="Huelsmeyer, Mk" uniqKey="Huelsmeyer M">MK Huelsmeyer</name></author><author><name sortKey="Dubielzig, Rr" uniqKey="Dubielzig R">RR Dubielzig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bird, Rc" uniqKey="Bird R">RC Bird</name></author><author><name sortKey="Deinnocentes, P" uniqKey="Deinnocentes P">P Deinnocentes</name></author><author><name sortKey="Church Bird, Ae" uniqKey="Church Bird A">AE Church Bird</name></author><author><name sortKey="Van Ginkel, Fw" uniqKey="Van Ginkel F">FW Van Ginkel</name></author><author><name sortKey="Lindquist, J" uniqKey="Lindquist J">J Lindquist</name></author><author><name sortKey="Smith, Bf" uniqKey="Smith B">BF Smith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sorenmo, Ku" uniqKey="Sorenmo K">KU Sorenmo</name></author><author><name sortKey="Krick, E" uniqKey="Krick E">E Krick</name></author><author><name sortKey="Coughlin, Cm" uniqKey="Coughlin C">CM Coughlin</name></author><author><name sortKey="Overley, B" uniqKey="Overley B">B Overley</name></author><author><name sortKey="Gregor, Tp" uniqKey="Gregor T">TP Gregor</name></author><author><name sortKey="Vonderheide, Rh" uniqKey="Vonderheide R">RH Vonderheide</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marconato, L" uniqKey="Marconato L">L Marconato</name></author><author><name sortKey="Frayssinet, P" uniqKey="Frayssinet P">P Frayssinet</name></author><author><name sortKey="Rouquet, N" uniqKey="Rouquet N">N Rouquet</name></author><author><name sortKey="Comazzi, S" uniqKey="Comazzi S">S Comazzi</name></author><author><name sortKey="Leone, Vf" uniqKey="Leone V">VF Leone</name></author><author><name sortKey="Laganga, P" uniqKey="Laganga P">P Laganga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="U Ren, Lw" uniqKey="U Ren L">LW U'Ren</name></author><author><name sortKey="Biller, Bj" uniqKey="Biller B">BJ Biller</name></author><author><name sortKey="Elmslie, Re" uniqKey="Elmslie R">RE Elmslie</name></author><author><name sortKey="Thamm, Dh" uniqKey="Thamm D">DH Thamm</name></author><author><name sortKey="Dow, Sw" uniqKey="Dow S">SW Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergman, Pj" uniqKey="Bergman P">PJ Bergman</name></author><author><name sortKey="Mcknight, J" uniqKey="Mcknight J">J Mcknight</name></author><author><name sortKey="Novosad, A" uniqKey="Novosad A">A Novosad</name></author><author><name sortKey="Charney, S" uniqKey="Charney S">S Charney</name></author><author><name sortKey="Farrelly, J" uniqKey="Farrelly J">J Farrelly</name></author><author><name sortKey="Craft, D" uniqKey="Craft D">D Craft</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergman, Pj" uniqKey="Bergman P">PJ Bergman</name></author><author><name sortKey="Camps Palau, Ma" uniqKey="Camps Palau M">MA Camps-Palau</name></author><author><name sortKey="Mcknight, Ja" uniqKey="Mcknight J">JA Mcknight</name></author><author><name sortKey="Leibman, Nf" uniqKey="Leibman N">NF Leibman</name></author><author><name sortKey="Craft, Dm" uniqKey="Craft D">DM Craft</name></author><author><name sortKey="Leung, C" uniqKey="Leung C">C Leung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamstock, D" uniqKey="Kamstock D">D Kamstock</name></author><author><name sortKey="Elmslie, R" uniqKey="Elmslie R">R Elmslie</name></author><author><name sortKey="Thamm, D" uniqKey="Thamm D">D Thamm</name></author><author><name sortKey="Dow, S" uniqKey="Dow S">S Dow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gavazza, A" uniqKey="Gavazza A">A Gavazza</name></author><author><name sortKey="Lubas, G" uniqKey="Lubas G">G Lubas</name></author><author><name sortKey="Fridman, A" uniqKey="Fridman A">A Fridman</name></author><author><name sortKey="Peruzzi, D" uniqKey="Peruzzi D">D Peruzzi</name></author><author><name sortKey="Impellizeri, Ja" uniqKey="Impellizeri J">JA Impellizeri</name></author><author><name sortKey="Luberto, L" uniqKey="Luberto L">L Luberto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mason, Nj" uniqKey="Mason N">NJ Mason</name></author><author><name sortKey="Gnanandarajah, Js" uniqKey="Gnanandarajah J">JS Gnanandarajah</name></author><author><name sortKey="Engiles, Jb" uniqKey="Engiles J">JB Engiles</name></author><author><name sortKey="Gray, F" uniqKey="Gray F">F Gray</name></author><author><name sortKey="Laughlin, D" uniqKey="Laughlin D">D Laughlin</name></author><author><name sortKey="Gaurnier Hausser, A" uniqKey="Gaurnier Hausser A">A Gaurnier-Hausser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mie, K" uniqKey="Mie K">K Mie</name></author><author><name sortKey="Shimada, T" uniqKey="Shimada T">T Shimada</name></author><author><name sortKey="Akiyoshi, H" uniqKey="Akiyoshi H">H Akiyoshi</name></author><author><name sortKey="Hayashi, A" uniqKey="Hayashi A">A Hayashi</name></author><author><name sortKey="Ohashi, F" uniqKey="Ohashi F">F Ohashi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Connor, Cm" uniqKey="O Connor C">CM O'Connor</name></author><author><name sortKey="Sheppard, S" uniqKey="Sheppard S">S Sheppard</name></author><author><name sortKey="Hartline, Ca" uniqKey="Hartline C">CA Hartline</name></author><author><name sortKey="Huls, H" uniqKey="Huls H">H Huls</name></author><author><name sortKey="Johnson, M" uniqKey="Johnson M">M Johnson</name></author><author><name sortKey="Palla, Sl" uniqKey="Palla S">SL Palla</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hwang, Cc" uniqKey="Hwang C">CC Hwang</name></author><author><name sortKey="Igase, M" uniqKey="Igase M">M Igase</name></author><author><name sortKey="Sakurai, M" uniqKey="Sakurai M">M Sakurai</name></author><author><name sortKey="Haraguchi, T" uniqKey="Haraguchi T">T Haraguchi</name></author><author><name sortKey="Tani, K" uniqKey="Tani K">K Tani</name></author><author><name sortKey="Itamoto, K" uniqKey="Itamoto K">K Itamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Naik, S" uniqKey="Naik S">S Naik</name></author><author><name sortKey="Galyon, Gd" uniqKey="Galyon G">GD Galyon</name></author><author><name sortKey="Jenks, Nj" uniqKey="Jenks N">NJ Jenks</name></author><author><name sortKey="Steele, Mb" uniqKey="Steele M">MB Steele</name></author><author><name sortKey="Miller, Ac" uniqKey="Miller A">AC Miller</name></author><author><name sortKey="Allstadt, Sd" uniqKey="Allstadt S">SD Allstadt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Panjwani, Mk" uniqKey="Panjwani M">MK Panjwani</name></author><author><name sortKey="Smith, Jb" uniqKey="Smith J">JB Smith</name></author><author><name sortKey="Schutsky, K" uniqKey="Schutsky K">K Schutsky</name></author><author><name sortKey="Gnanandarajah, J" uniqKey="Gnanandarajah J">J Gnanandarajah</name></author><author><name sortKey="O Connor, Cm" uniqKey="O Connor C">CM O'Connor</name></author><author><name sortKey="Powell, Dj" uniqKey="Powell D">DJ Powell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Walsh, P" uniqKey="Walsh P">P Walsh</name></author><author><name sortKey="Gonzalez, R" uniqKey="Gonzalez R">R Gonzalez</name></author><author><name sortKey="Dow, S" uniqKey="Dow S">S Dow</name></author><author><name sortKey="Elmslie, R" uniqKey="Elmslie R">R Elmslie</name></author><author><name sortKey="Potter, T" uniqKey="Potter T">T Potter</name></author><author><name sortKey="Glode, Lm" uniqKey="Glode L">LM Glode</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yuan, J" uniqKey="Yuan J">J Yuan</name></author><author><name sortKey="Ku, Gy" uniqKey="Ku G">GY Ku</name></author><author><name sortKey="Adamow, M" uniqKey="Adamow M">M Adamow</name></author><author><name sortKey="Mu, Z" uniqKey="Mu Z">Z Mu</name></author><author><name sortKey="Tandon, S" uniqKey="Tandon S">S Tandon</name></author><author><name sortKey="Hannaman, D" uniqKey="Hannaman D">D Hannaman</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31803625</article-id><article-id pub-id-type="pmc">6873901</article-id><article-id pub-id-type="doi">10.3389/fonc.2019.01257</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Canine Cancer: Strategies in Experimental Therapeutics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thamm</surname><given-names>Douglas H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/783562/overview"></uri></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Flint Animal Cancer Center, Colorado State University</institution>,<addr-line>Fort Collins, CO</addr-line>,<country>United States</country></aff><aff id="aff2"><sup>2</sup><institution>Cell and Molecular Biology Graduate Program, Colorado State University</institution>,<addr-line>Fort Collins, CO</addr-line>,<country>United States</country></aff><aff id="aff3"><sup>3</sup><institution>University of Colorado Cancer Center, Anschutz Medical Campus</institution>,<addr-line>Aurora, CO</addr-line>,<country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Mark W. Dewhirst, Duke University, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Terence S. Herman, University of Oklahoma Health Sciences Center, United States; Allison B. Warner, Memorial Sloan Kettering Cancer Center, United States; Amy LeBlanc, National Cancer Institute (NCI), United States</p></fn><corresp id="c001">*Correspondence: Douglas H. Thamm <email>dthamm@colostate.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>9</volume><elocation-id>1257</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>Copyright © 2019 Thamm.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Thamm</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Cancer is the most common cause of death in adult dogs. Many features of spontaneously developing tumors in pet dogs contribute to their potential utility as a human disease model. These include similar environmental exposures, similar clonal evolution as it applies to important factors such as immune avoidance, a favorable body size for imaging and serial biopsy, and a relatively contracted time course of disease progression, which makes evaluation of temporal endpoints such as progression free or overall survival feasible in a comparatively short time frame. These criteria have been leveraged to evaluate novel local therapies, demonstrate proof of tumor target inhibition or tumor localization, evaluate potential antimetastatic approaches, and assess the efficacy, safety and immune effects of a variety of immune-based therapeutics. Some of these canine proof of concept studies have been instrumental in informing subsequent human clinical trials. This review will cover key aspects of clinical trials in dogs with spontaneous neoplasia, with examples of how these studies have contributed to human cancer therapeutic development.</p></abstract><kwd-group><kwd>dog</kwd><kwd>tumor</kwd><kwd>clinical trial</kwd><kwd>translational</kwd><kwd>animal model</kwd></kwd-group><counts><fig-count count="0"></fig-count><table-count count="1"></table-count><equation-count count="0"></equation-count><ref-count count="131"></ref-count><page-count count="9"></page-count><word-count count="8331"></word-count></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Common concerns with regard to the clinical applicability of many murine models of human cancer include immune status, significantly reduced clonal heterogeneity, relative tumor burden, tumor location (orthotopic vs. heterotopic), species-specific differences in drug distribution/metabolism, and differences in <italic>in vivo</italic> drug concentrations that are achievable, among others. These contribute to the observation of extremely poor correlation between results of murine studies and early human clinical trials with anticancer agents (<xref rid="B1" ref-type="bibr">1</xref>). More predictive animal models are clearly needed.</p><p>More than 1 million new cases of cancer are thought to occur in dogs each year in the United States, and in retrospective studies describing canine mortality, cancer is the most common cause of death with an estimated rate of ~30% (<xref rid="B2" ref-type="bibr">2</xref>–<xref rid="B4" ref-type="bibr">4</xref>). This large cancer burden in dogs indicates a group of spontaneously occurring tumors, many of which are histologically similar to human tumors. Commonly encountered histotypes include non-Hodgkin lymphoma, malignant melanoma, osteosarcoma (OSA), bladder carcinoma, and multiple brain cancer types among others (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Client-owned dogs with cancer are being increasingly recognized as a resource for preclinical interrogation of the tolerability, pharmacology, pharmacodynamic effects, and potential efficacy of novel anticancer therapies. This model's potential was discussed in a National Academy of Medicine Workshop on Comparative Oncology that occurred in 2015 (<ext-link ext-link-type="uri" xlink:href="http://www.nap.edu/21830">http://www.nap.edu/21830</ext-link>) (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Clinical trials in client-owned dogs with spontaneous cancer are potentially important translational models, owing to dogs' relative outbreeding, large size, immunocompetence, and physiological/biological similarity to humans. Spontaneous canine tumors naturally develop treatment resistance, as well as spontaneous recurrence and metastasis. Absolute tumor burdens in dogs are more similar to humans, which may be informative with regard to biological factors such as clonal heterogeneity and hypoxia. The comparatively large size of canine tumors (vs. rodent tumors) also allows for serial tissue collection and imaging over time (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B7" ref-type="bibr">7</xref>). This is due partly to the fact that these patients are commonly sedated or anesthetized for procedures, moderating concerns over patient discomfort. While clinical case management and data collection are of very high quality, the relative cost of veterinary oncology clinical trials are 10–20% of what similar trials in physician-based oncology would be.</p><p>Dogs may also be more reliable models for assessing toxicity of novel therapies than are rodents. As in human patients, canine patients are monitored for hematologic and biochemical toxicities via routine clinical pathology, and sophisticated monitoring (e.g., 24 hour continuous electrocardiographic telemetry, continuous blood pressure measurement, ophthalmologic monitoring, echocardiography, gait analysis, advanced imaging) can be performed as-needed. Unlike in laboratory settings, supportive care (e.g., antiemetics, antidiarrheals, antibiotics, etc.) is also used in client-owned animals similarly to its employment in human patients. Universally accepted grading systems for adverse events from antineoplastic therapy (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>), as well as universally accepted tumor response criteria (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>), are published.</p><p>The Comparative Oncology Trials Consortium (COTC: <ext-link ext-link-type="uri" xlink:href="https://ccr.cancer.gov/Comparative-Oncology-Program/sponsors/consortium">https://ccr.cancer.gov/Comparative-Oncology-Program/sponsors/consortium</ext-link>) is a network of more than 20 academic veterinary oncology centers, centrally managed by the Comparative Oncology Program, housed within the NIH-NCI-Center for Cancer Research. Its central goal is to plan and perform clinical trials in dogs with cancer to evaluated novel potential therapies for human cancer, with the goal of answering biological questions to inform development for future human clinical trials. COTC sponsored trials are usually pharmacokinetically/pharmacodynamically intensive, with the results incorporated into the design of future human studies. The launch of this network has improved the ability of potential sponsors and collaborators to access a national cooperative group for the conduct of proof of concept studies in dogs. Potential sponsors work with COTC management to iteratively develop a clinical protocol to address a specific drug development question/questions, which is then put out to the membership for potential participation. COTC sites have the opportunity to participate or decline based on capacity, specialized equipment/techniques that may be required, and/or competing trials at the institution. Trial conduct is governed by a single memorandum of understanding between the participating sites, which streamlines the contractual process.</p><p>These important attributes have allowed the preclinical evaluation of novel cancer therapeutics that fall into several broad categories: (1) Local therapy approaches such as surgery, radiation therapy and locally-delivered drug therapy; (2) Proof of target inhibition and proof of tumor targeting; (3) Studies in the minimal residual disease setting; (4) Immunotherapy studies.</p></sec><sec id="s2"><title>Local Therapy Approaches</title><p>As a result of dogs' comparatively large body size and the relative size of their tumors, tumor-bearing dogs can be a unique and informative model for the evaluation of novel local therapies. Surgical and radiation therapy (RT) related studies can utilize the same techniques and equipment as would be used in human patients, without the need for the significant adaptation or miniaturization which could be required for rodents. As stated above, the comparatively similar size and growth rate of dog tumors results in similarities in important microenvironmental parameters such as oxygenation, pH, and interstitial fluid pressure (<xref rid="B12" ref-type="bibr">12</xref>–<xref rid="B18" ref-type="bibr">18</xref>), and the large tumor size facilitates serial biopsy and measurement of intratumoral parameters over time. As a result, tumor-bearing dogs have been utilized in translational studies of novel surgical approaches, RT, hyperthermia, and regionally-delivered drug therapy.</p><sec><title>Translational Surgical Studies</title><p>National Cancer Institute sponsored work by Withrow et al. in the 1980's pioneered surgical protocols for cortical allografts for limb-salvage in bone sarcoma patients. These procedures were co-developed by veterinary and human surgical oncologists and refined in a large number of dogs with spontaneous OSA, mostly of the distal radius. Effects of neoadjuvant RT and chemotherapy on surgical outcome and allograft incorporation were also assessed (<xref rid="B19" ref-type="bibr">19</xref>–<xref rid="B21" ref-type="bibr">21</xref>). These observations and subsequent refinements developed in dogs led directly to the use of these approaches in human limb-sparing surgery (<xref rid="B22" ref-type="bibr">22</xref>). An observation was made regarding the postoperative development of bacterial osteomyelitis and improved metastasis-free and overall survival times in dogs (<xref rid="B23" ref-type="bibr">23</xref>). This was subsequently observed in at least one study of humans with OSA (<xref rid="B24" ref-type="bibr">24</xref>). Further study of this observation in a murine syngeneic OSA model suggested NK- and monocyte-mediated angiogenesis inhibition as a putative mechanism of action (<xref rid="B25" ref-type="bibr">25</xref>).</p></sec><sec><title>Radiation Therapy</title><p>Studies of radiation by Gillette et al. in the 1970's and 1980's in both normal and tumor-bearing dogs established many normal tissue RT dose constraints still in use today in human patients (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B26" ref-type="bibr">26</xref>–<xref rid="B37" ref-type="bibr">37</xref>). More recently, studies in tumor-bearing dogs provided critical proof of concept for accurate dosimetry and conformal avoidance during the development of helical tomotherapy, a slice-by-slice image-guided intensity modulated RT strategy that is now commercially available (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>).</p></sec><sec><title>Translational Studies of Hyperthermia and Radiation Therapy</title><p>A substantial body of literature documents pioneering NCI-funded work by Dewhirst et al. evaluating the effects of hyperthermia and hyperthermia/RT combinations on the tumor microenvironment in canine tumors, especially soft-tissue sarcomas. As a result of their common subcutaneous location and the relative ease with which procedures such as serial biopsy and interstitial probe placement can be performed, meaningful insights into thermal dosimetry, alterations in tumor perfusion and tumor oxygenation, and predictors of clinical response were identified (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B40" ref-type="bibr">40</xref>–<xref rid="B42" ref-type="bibr">42</xref>).</p></sec><sec><title>Locally/Regionally Delivered Therapeutics</title><p>Multiple studies of inhaled/pulmonary delivered therapeutics have evaluated safety and provided preliminary evidence of antitumor efficacy in support of human trials. These include evaluation of inhaled doxorubicin, paclitaxel and gemcitabine for the treatment of measurable primary or metastatic pulmonary tumors (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>), and nebulized inhaled interleukin-2 (IL-2) containing liposomes for treatment of pulmonary metastatic OSA (<xref rid="B45" ref-type="bibr">45</xref>). In addition to the observed objective antitumor responses, the latter study included serially collected bronchoalveolar lavage (BAL) fluid to characterize the local leukocyte population before and after IL-2 therapy. Post-IL-2 BAL samples contained a more than four-fold increase in lymphocytes, with a shifted CD4:CD8 ratio and increased cytolytic activity <italic>ex vivo</italic> (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>Various intratumor treatments have been evaluated in tumor-bearing dog models. These include attenuated <italic>Clostridium</italic> spores (<xref rid="B46" ref-type="bibr">46</xref>), and various intralesional gene therapy approaches (<xref rid="B47" ref-type="bibr">47</xref>–<xref rid="B50" ref-type="bibr">50</xref>). In many of these studies, serial biopsy was performed to evaluate and characterize immune infiltrates and/or confirm transgene expression. Several novel intralesional chemotherapy approaches (± other local treatments such as RT or hyperthermia) have likewise been evaluated, demonstrating tolerability and preliminary evidence of efficacy (<xref rid="B50" ref-type="bibr">50</xref>–<xref rid="B55" ref-type="bibr">55</xref>).</p></sec></sec><sec id="s3"><title>Proof of Target Inhibition or Proof of Tumor Targeting/Accumulation</title><p>Owing again to the relative ease of serial biopsy, as well as comparably favorable pharmacokinetic parameters in dogs such as organ-specific blood flow and hepatic enzyme homologies, canine tumors can serve as very useful translational models for evaluation of pharmacokinetic/pharmacodynamic (PK/PD) relationships, demonstration of target inhibition, and/or demonstration of tumor targeting. In these cases, substantial preliminary <italic>in vitro</italic> work is often necessary to confirm target expression, demonstrate similar drug behavior in canine and human tumor cells, and potentially validate reagents and protocols necessary for PD assessment. Importantly, there are certain situations where molecular targets may be present in canine tumors that are histologically very different from human tumors expressing the same target. Examples include expression of mutant KIT protein in canine mast cell tumors (MCT) with a similar mutation expressed in human gastrointestinal stromal tumors (<xref rid="B56" ref-type="bibr">56</xref>), and expression of the V600E BRAF mutation, commonly expressed in human melanomas, in canine bladder cancer (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>).</p><sec><title>Proof of Drug Target Inhibition</title><p>An early example of successful evaluation of a novel targeted agent in dogs with spontaneous neoplasia involves the preclinical evaluation of the “split kinase” inhibitor SU11654 (toceranib phosphate, Palladia™), in dogs with MCT. SU11654 is a structural analog of the human multi-kinase inhibitor sunitinib (Sutent™) with very similar physicochemical properties and IC50's against their intended targets, which include KIT, VEGFR2 and PDGFR-alpha. After initial <italic>in vitro</italic> studies demonstrating canine MCT growth inhibition, apoptosis induction and inhibition of KIT phosphorylation (<xref rid="B59" ref-type="bibr">59</xref>), pilot studies were performed in tumor-bearing dogs demonstrating achievement of likely therapeutic drug concentrations in plasma with good tolerability and evidence of antitumor activity (<xref rid="B60" ref-type="bibr">60</xref>). Furthermore, inhibition of KIT activation and downstream signaling was demonstrated in biopsy samples prior to and 8 h following the first dose of drug (<xref rid="B61" ref-type="bibr">61</xref>). These data provided critical information in support of the human development of sunitinib, which is now approved by the U.S. Food and Drug Administration (FDA) for human renal cell carcinoma, pancreatic neuroendocrine tumors, and gastrointestinal stromal tumors, and led to the FDA approval of toceranib for the treatment of canine MCT (<xref rid="B62" ref-type="bibr">62</xref>).</p><p>A similar “next to lead” approach has been taken with the selective inhibitor of nuclear export verdinexor (KPT-335), which was evaluated <italic>in vitro</italic> for activity in canine tumor cells, then in tumor-bearing dogs to provide supporting data for development of the human analog selinexor (KPT-330, Xpovio™) (<xref rid="B63" ref-type="bibr">63</xref>), now approved by the FDA for the treatment of human multiple myeloma. Verdinexor is now in clinical development as a canine cancer therapeutic.</p><p>Rather than evaluating a structural analog to generate preclinical data in tumor-bearing dogs in support of a human clinical candidate, another recent study evaluated PCI-32765 (ibrutinib, Imbruvica™), a first-in-class inhibitor of the Bruton tyrosine kinase (Btk), in dogs with spontaneous B-cell lymphoma prior to first-in-in-human studies (<xref rid="B64" ref-type="bibr">64</xref>). Goals of the study were 2-fold: (1) To validate a PD assay to be used in subsequent human trials; (2) To generate preliminary evidence of efficacy, since reliable murine B-cell lymphoma models demonstrating intact B cell receptor signaling were not available. Btk receptor occupancy following ibrutinib treatment was similar in lymphoma tissue and peripheral blood following treatment, providing support that measurement in blood alone would likely be accurate in humans. Furthermore, major antitumor responses were observed in three of eight dogs treated, providing strong impetus to accelerate human clinical development of ibrutinib. Ibrutinib now has FDA approval in humans for the treatment of certain B cell lymphoma subtypes, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia and graft-vs.-host disease.</p></sec><sec><title>Proof of Tumor Targeting</title><p>Canine tumors have been utilized to confirm tumor-specific targeting and/or tumor accumulation of therapeutics. The inaugural COTC trial evaluated a tumor vasculature targeted adeno-associated virus phage vector targeted to alphaV integrins expressed on tumor endothelium and delivering tumor necrosis factor (TNF), in preparation for human trials. Selective targeting of tumor (vs. normal) vasculature was documented through serial biopsy of tumor and proximate normal tissues after intravenous infusion, and tumor-directed expression of TNF was documented. Furthermore, objective antitumor responses were noted in 2 of 14 dogs (<xref rid="B65" ref-type="bibr">65</xref>).</p><p>Certain bacteria, especially facultative anaerobes, demonstrate tropism for tumor tissues. VNP20009 is a <italic>Salmonella typhimurium</italic> strain that was attenuated through deletion of the <italic>MsbB</italic> gene, contributing to endotoxin production, and the PurI gene, requiring an exogenous source of purines for survival. These deletions reduce toxicity and further restrict colonization to tumor tissues <italic>in vivo</italic>, while diminishing or eliminating survival in the environment. Intravenous infusion of VNP20009 was evaluated in tumor-bearing dogs for safety and evidence of tumor colonization (<xref rid="B66" ref-type="bibr">66</xref>). While blood cultures were uniformly negative 7 days following infusion, the organism was isolated from tumor tissue in 42% of dogs. The objective response rate was 15% (10% complete responses). These data supported an NCI-sponsored clinical trial of VNP20009 in human metastatic melanoma (<xref rid="B67" ref-type="bibr">67</xref>). No objective antitumor responses were observed in the human melanoma study, however; this could be due to selection of melanoma as the sole human tumor type for study, or due to differences in either tolerability or host (e.g., immune, vascular) response to the bacterium between dog and human. Strategies for geographically targeted cytotoxic drug delivery via hyperthermia and thermosensitive liposomes have also been investigated in canine soft tissue sarcomas (<xref rid="B68" ref-type="bibr">68</xref>).</p></sec><sec><title>Proof of Tumor Drug Accumulation</title><p>A recent canine clinical trial of the autophagy modulating agent hydroxychloroquine (HCQ), which was published concurrently with a series of human clinical trials, was the first to document substantial accumulation (~100-fold) of HCQ in tumor tissue when compared with plasma, and to demonstrate that there was no correlation between drug concentrations or changes in autophagy in the two compartments. This suggested that peripheral blood is not a good surrogate for tumor HCQ concentration or autophagy-modulatory activity, and that future clinical trials should aim to identify more accurate surrogates of HCQ activity (<xref rid="B69" ref-type="bibr">69</xref>).</p><p>Another large COTC trial evaluated a series of three distinct indenoisoquinolone-class topoisomerase I inhibitors in dogs with spontaneous lymphoma. Eighty-four dogs with lymphoma were allocated to receive one of three drugs. Tolerability, pharmacokinetics, target engagement and antitumor effects were evaluated. One of the three drugs, LMP744, demonstrated significantly increased accumulation in tumor tissue vs. the other two drugs, and enhanced antitumor activity was ascribed to this increased tumor accumulation (<xref rid="B70" ref-type="bibr">70</xref>). Although LMP744 was not originally selected for further human development, the unexpected positive results of the canine trial encouraged the NCI to evaluate LMP744 in humans (<ext-link ext-link-type="uri" xlink:href="https://www.ClinicalTrials.govidentifierNCT03030417">ClinicalTrials.gov identifier NCT03030417</ext-link>). This human trial is currently accruing and thus human safety/efficacy data are not currently available.</p></sec></sec><sec id="s4"><title>Antimetastatic Efficacy</title><p>Another potential advantage of canine clinical cancer research is the relatively compressed time line for tumor progression and the spontaneous development of local recurrence, metastasis, and drug resistance. These characteristics allow surgical adjuvant studies against “microscopic residual disease,” with temporal endpoints such as progression free or overall survival, to be conducted relatively expediently. This may be useful especially for agents designed primarily as antimetastatic therapies. Several candidate human therapies have been investigated in this context in tumor-bearing dogs.</p><p>Extensive work by Macewen, Kurzman et al. with the peptidoglycan recognition protein agonist and non-specific immune stimulant liposome muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) was performed in dogs with hemangiosarcoma (HSA) and OSA. Randomized placebo controlled trials demonstrated meaningful delays in metastasis and prolongation of overall survival times when surgery and chemotherapy were combined with L-MTP-PE (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>). Furthermore, bronchoalveolar lavage performed before and after L-MTP-PE indicated significant enhancement of activation status and <italic>ex vivo</italic> antitumor cytotoxicity in pulmonary alveolar macrophages (<xref rid="B73" ref-type="bibr">73</xref>). This work provided critical proof of principle showing delay of metastasis in OSA, which led directly to the performance of a randomized, placebo-controlled trial of surgery, chemotherapy ± L-MTP-PE in human OSA (<xref rid="B74" ref-type="bibr">74</xref>). Subsequently, L-MTP-PE (mifamurtide, Mepact™) was granted regulatory approval by the European Medicines Agency for treatment of human OSA.</p><p>Another randomized, multicenter surgical adjuvant study compared standard-of-care therapy with carboplatin to treatment with the novel liposomal cisplatin drug SPI-77 in dogs with appendicular OSA. Despite SPI-77's capacity to deliver five times more cisplatin vs. the maximum tolerated dose of free cisplatin, there were no improvements in progression free survival time or overall survival time when compared with conventionally dosed carboplatin. These results, combined with other factors, contributed significantly to the decision to suspend SPI-77's clinical development (<xref rid="B75" ref-type="bibr">75</xref>).</p><p>In a recent study, dogs with splenic HSA were treated after splenectomy with a combination of doxorubicin and an epidermal growth factor receptor- and urokinase-targeted <italic>Pseudomonas</italic> exotoxin, referred to as eBAT. These targets appear to be conserved in certain human sarcomas, and thus canine HSA may be a valuable translational model despite the distinct histotype and rareness of its human homolog. In addition to very good tolerability, there was the suggestion of improved outcome when eBAT-treated patients were compared with historical canine patients receiving doxorubicin alone (<xref rid="B76" ref-type="bibr">76</xref>). The human development path for eBAT is not currently known.</p></sec><sec id="s5"><title>Immunotherapy</title><p>In addition to the advantages discussed above, a unique advantage of spontaneous canine tumors that has been somewhat overlooked is that these tumors have evolved, by necessity, immune-avoidance strategies that are very similar to those utilized by human cancers. This is in stark contrast to syngeneic murine tumor models, where immune tolerance does not evolve similarly. These immune-avoidance strategies include upregulation of immune-suppressive cytokines such as IL-8, IL-10, and transforming growth factor beta (<xref rid="B77" ref-type="bibr">77</xref>–<xref rid="B80" ref-type="bibr">80</xref>), cooptation of innate immune-suppressive cells such as regulatory T cells (<xref rid="B81" ref-type="bibr">81</xref>–<xref rid="B83" ref-type="bibr">83</xref>), myeloid-derived suppressor cells (<xref rid="B84" ref-type="bibr">84</xref>–<xref rid="B86" ref-type="bibr">86</xref>), and “steady state” macrophages (<xref rid="B87" ref-type="bibr">87</xref>–<xref rid="B90" ref-type="bibr">90</xref>), and upregulation of immune checkpoint molecules such as PD-L1 and B7x (<xref rid="B91" ref-type="bibr">91</xref>–<xref rid="B95" ref-type="bibr">95</xref>). Thus, successful cancer immunotherapy in dogs requires overcoming of these conserved immune-avoidance strategies just as is required in humans.</p><p>In addition to the approaches mentioned in previous sections, a variety of immunotherapy strategies have been investigated in dogs over decades. These range from passive non-specific immunotherapy approaches to early studies with canine chimeric antigen receptor-engineered T (CAR-T) cells. A partial list of immunotherapy approaches investigated in dogs with cancer is provided in <xref rid="T1" ref-type="table">Table 1</xref>. An exhaustive discussion of these approaches is beyond the scope of this review; however, this issue contains a dedicated article discussing canine tumor immunology and immunotherapy. Several of the approaches outlined in the Table have led to human clinical trials (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Immunotherapy approaches investigated in canine cancer trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Category</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Therapy type</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Passive, nonspecific</td><td valign="top" align="left" rowspan="1" colspan="1">BCG/other bacterial products</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B96" ref-type="bibr">96</xref>–<xref rid="B100" ref-type="bibr">100</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">L-MTP-PE</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B71" ref-type="bibr">71</xref>–<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B101" ref-type="bibr">101</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant cytokines</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B101" ref-type="bibr">101</xref>–<xref rid="B107" ref-type="bibr">107</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Intralesional immuno/gene therapy</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B108" ref-type="bibr">108</xref>–<xref rid="B110" ref-type="bibr">110</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Passive, specific</td><td valign="top" align="left" rowspan="1" colspan="1">Tumor-targeting antibodies</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Checkpoint inhibitors</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">113</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Whole cell vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B114" ref-type="bibr">114</xref>–<xref rid="B119" ref-type="bibr">119</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Gene/peptide vaccines</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B120" ref-type="bibr">120</xref>–<xref rid="B124" ref-type="bibr">124</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Active, nonspecific</td><td valign="top" align="left" rowspan="1" colspan="1">Activated T cells</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>)</td></tr><tr><td rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Oncolytic virotherapy</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Active, specific</td><td valign="top" align="left" rowspan="1" colspan="1">CAR-T cells</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B129" ref-type="bibr">129</xref>)</td></tr></tbody></table></table-wrap></sec><sec id="s6"><title>Conclusions and Future Directions</title><p>In conclusion, there is great potential for studies in dogs with spontaneous cancer to inform development of novel human therapeutics and diagnostics. In general, these studies have a higher potential for success when there is a focused, <italic>a priori</italic> question that canine studies seek to answer, and a plan for utilization of the data generated is in place prior to study commencement. Additionally, utilizing the strengths of the model, especially vis a vis the ability to repeatedly sample tumor tissue, to generate robust PK/PD related data is value-added. These types of data are perhaps more critical in answering questions regarding why a treatment did not work than in supporting how a treatment did work. Was it an issue of insufficient drug exposure? Was there adequate exposure in plasma but not tumor? Was the target appropriately inhibited despite a lack of antitumor activity?</p><p>Additionally, successful implementation of studies in dogs generally requires some amount of preclinical work for validation of target expression, validation of drug activity against the canine analog of the target, and selection/validation of PD endpoints to be implemented in subsequent canine clinical trials. A lack of canine-specific reagents often requires some legwork for the validation of cross-reactive antibodies for these types of applications.</p><p>Ongoing foundational work has the potential to significantly expand the molecular underpinnings of canine cancer, and facilitate comparisons with human cancer. A number of 1 year administrative supplements to existing NIH P30 grants were recently approved, with the goals of utilizing next-gen sequencing (whole-exome sequencing, RNASeq) to characterize a variety of canine tumor types for quantification of mutational load, identification of driver mutations, and characterization of potential neoantigens for MHC binding. Furthermore, a series of U01 grants were recently funded by the NIH to explore novel immunotherapy approaches in canine cancer to inform human cancer immunotherapy studies. These studies have the potential to expand understanding of the molecular drivers of canine cancer and uncover novel shared molecular targets and pathways for future study.</p><p>Several ongoing large-scale longitudinal studies are taking advantage of dogs' foreshortened life spans to answer a variety of questions about life style, environment, aging and cancer incidence, as well as evaluating novel interventions. The Golden Retriever Lifetime Health Study (<ext-link ext-link-type="uri" xlink:href="http://www.morrisanimalfoundation.org/golden">www.morrisanimalfoundation.org/golden</ext-link>-retriever-lifetime-study) is following 3,000 US golden retrievers from young adulthood to death, to identify environmental, nutritional, genetic, and lifestyle risk factors for cancer and other diseases in dogs. The University of Washington Dog Aging Project (<ext-link ext-link-type="uri" xlink:href="https://dogagingproject.org">https://dogagingproject.org</ext-link>) seeks to profile and follow up to 10,000 dogs to determine incidence and risk factors for a variety of age-related diseases, as well as pursuing smaller-scale trials with novel anti-aging (and potentially anti-cancer) interventions. The Vaccination Against Canine Cancer Study (<ext-link ext-link-type="uri" xlink:href="http://www.vaccs.org">www.vaccs.org</ext-link>) is an 800-dog, randomized, placebo-controlled, prospective, multi-center clinical trial seeking to evaluate the evaluate the ability of a multivalent frameshift vaccine to delay or prevent cancer development in healthy older dogs. These three long-term studies have the potential to shed significant light on genetic, environmental, lifestyle, and immunologic risk factors for cancer that may have significant translatability. The results are eagerly anticipated.</p></sec><sec id="s7"><title>Author Contributions</title><p>The author confirms being the sole contributor of this work and has approved it for publication.</p><sec><title>Conflict of Interest</title><p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JI</given-names></name><name><surname>Decker</surname><given-names>S</given-names></name><name><surname>Zaharevitz</surname><given-names>D</given-names></name><name><surname>Rubinstein</surname><given-names>LV</given-names></name><name><surname>Venditti</surname><given-names>JM</given-names></name><name><surname>Schepartz</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Relationships between drug activity in NCI preclinical <italic>in vitro</italic> and <italic>in vivo</italic> models and early clinical trials</article-title>. <source>Br J Cancer</source>. (<year>2001</year>) <volume>84</volume>:<fpage>1424</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1054/bjoc.2001.1796</pub-id><pub-id pub-id-type="pmid">11355958</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoloni</surname><given-names>M</given-names></name><name><surname>Khanna</surname><given-names>C</given-names></name></person-group>. <article-title>Translation of new cancer treatments from pet dogs to humans</article-title>. <source>Nat Rev Cancer</source>. (<year>2008</year>) <volume>8</volume>:<fpage>147</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2273</pub-id><pub-id pub-id-type="pmid">18202698</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>JM</given-names></name><name><surname>Creevy</surname><given-names>KE</given-names></name><name><surname>Promislow</surname><given-names>DE</given-names></name></person-group>. <article-title>Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death</article-title>. <source>J Vet Intern Med</source>. (<year>2011</year>) <volume>25</volume>:<fpage>187</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-1676.2011.0695.x</pub-id><pub-id pub-id-type="pmid">21352376</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>CE</given-names></name></person-group>. <article-title>Naturally occurring cancers in dogs: insights for translational genetics and medicine</article-title>. <source>ILAR J</source>. (<year>2014</year>) <volume>55</volume>:<fpage>16</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1093/ilar/ilu010</pub-id><pub-id pub-id-type="pmid">24936028</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblanc</surname><given-names>AK</given-names></name><name><surname>Mazcko</surname><given-names>CN</given-names></name><name><surname>Khanna</surname><given-names>C</given-names></name></person-group>. <article-title>Defining the value of a comparative approach to cancer drug development</article-title>. <source>Clin Cancer Res</source>. (<year>2016</year>) <volume>22</volume>:<fpage>2133</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2347</pub-id><pub-id pub-id-type="pmid">26712689</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblanc</surname><given-names>AK</given-names></name><name><surname>Breen</surname><given-names>M</given-names></name><name><surname>Choyke</surname><given-names>P</given-names></name><name><surname>Dewhirst</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>TM</given-names></name><name><surname>Gustafson</surname><given-names>DL</given-names></name><etal></etal></person-group>. <article-title>Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology</article-title>. <source>Sci Transl Med</source>. (<year>2016</year>) <volume>8</volume>:<fpage>324ps325</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaf0746</pub-id><pub-id pub-id-type="pmid">26843188</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>Thamm</surname><given-names>DH</given-names></name></person-group><article-title>Spontaneously occurring tumors in companion animals as models for drug development</article-title>. In: <person-group person-group-type="editor"><name><surname>Teicher</surname><given-names>BA</given-names></name><name><surname>Andrews</surname><given-names>PA</given-names></name></person-group> editors. <source>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</source>, <edition>2nd ed</edition><publisher-loc>Totowa, NJ</publisher-loc>: <publisher-name>Humana Press</publisher-name> (<year>2004</year>). p. <fpage>259</fpage>–<lpage>84</lpage>.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladue</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>MK</given-names></name><collab>Veterinary Radiation Therapy Oncology G</collab></person-group>. <article-title>Toxicity criteria of the veterinary radiation therapy oncology group</article-title>. <source>Vet Radiol Ultrasound</source>. (<year>2001</year>) <volume>42</volume>:<fpage>475</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1740-8261.2001.tb00973.x</pub-id><pub-id pub-id-type="pmid">11678573</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Veterinary Cooperative Oncology Group</collab></person-group>. <article-title>Veterinary Cooperative Oncology Group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1</article-title>. <source>Vet Comp Oncol</source>. (<year>2016</year>) <volume>14</volume>:<fpage>417</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/vco.283</pub-id><pub-id pub-id-type="pmid">28530307</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>Michels</surname><given-names>GM</given-names></name><name><surname>Khanna</surname><given-names>C</given-names></name><name><surname>Selting</surname><given-names>KA</given-names></name><name><surname>London</surname><given-names>CA</given-names></name><collab>Veterinary Cooperative Oncology G</collab></person-group>. <article-title>Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)–a Veterinary Cooperative Oncology Group (VCOG) consensus document</article-title>. <source>Vet Comp Oncol.</source> (<year>2010</year>) <volume>8</volume>:<fpage>28</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5829.2009.00200.x</pub-id><pub-id pub-id-type="pmid">20230579</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>SM</given-names></name><name><surname>Thamm</surname><given-names>DH</given-names></name><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>London</surname><given-names>CA</given-names></name></person-group><article-title>Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document</article-title>. <source>Vet Comp Oncol</source>. (<year>2015</year>) <volume>13</volume>:<fpage>176</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1111/vco.12032</pub-id><pub-id pub-id-type="pmid">23534501</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cline</surname><given-names>JM</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Franko</surname><given-names>AJ</given-names></name><name><surname>Raleigh</surname><given-names>JA</given-names></name></person-group><article-title>Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours</article-title>. <source>Br J Cancer</source>. (<year>1990</year>) <volume>62</volume>:<fpage>925</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.1990.411</pub-id><pub-id pub-id-type="pmid">1701659</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeman</surname><given-names>EM</given-names></name><name><surname>Calkins</surname><given-names>DP</given-names></name><name><surname>Cline</surname><given-names>JM</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Raleigh</surname><given-names>JA</given-names></name></person-group>. <article-title>The relationship between proliferative and oxygenation status in spontaneous canine tumors</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1993</year>) <volume>27</volume>:<fpage>891</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(93)90465-8</pub-id><pub-id pub-id-type="pmid">8244820</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cline</surname><given-names>JM</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Rosner</surname><given-names>GL</given-names></name><name><surname>Raleigh</surname><given-names>JA</given-names></name></person-group>. <article-title>Distribution of the hypoxia marker CCI-103F in canine tumors</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1994</year>) <volume>28</volume>:<fpage>921</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(94)90113-9</pub-id><pub-id pub-id-type="pmid">8138446</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raleigh</surname><given-names>JA</given-names></name><name><surname>Zeman</surname><given-names>EM</given-names></name><name><surname>Calkins</surname><given-names>DP</given-names></name><name><surname>Mcentee</surname><given-names>MC</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name></person-group>. <article-title>Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors</article-title>. <source>Acta Oncol</source>. (<year>1995</year>) <volume>34</volume>:<fpage>345</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3109/02841869509093987</pub-id><pub-id pub-id-type="pmid">7779421</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cline</surname><given-names>JM</given-names></name><name><surname>Rosner</surname><given-names>GL</given-names></name><name><surname>Raleigh</surname><given-names>JA</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name></person-group>. <article-title>Quantification of CCI-103F labeling heterogeneity in canine solid tumors</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1997</year>) <volume>37</volume>:<fpage>655</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0360-3016(96)00559-7</pub-id><pub-id pub-id-type="pmid">9112464</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Rosner</surname><given-names>GL</given-names></name><name><surname>Azuma</surname><given-names>C</given-names></name><name><surname>Mcentee</surname><given-names>MC</given-names></name><name><surname>Raleigh</surname><given-names>JA</given-names></name></person-group>. <article-title>Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning</article-title>. <source>Radiother Oncol</source>. (<year>1997</year>) <volume>44</volume>:<fpage>171</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0167-8140(97)01931-2</pub-id><pub-id pub-id-type="pmid">9288846</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zachos</surname><given-names>TA</given-names></name><name><surname>Aiken</surname><given-names>SW</given-names></name><name><surname>Diresta</surname><given-names>GR</given-names></name><name><surname>Healey</surname><given-names>JH</given-names></name></person-group>. <article-title>Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors</article-title>. <source>Clin Orthop Relat Res</source>. (<year>2001</year>) <fpage>230</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/00003086-200104000-00034</pub-id><pub-id pub-id-type="pmid">11302319</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larue</surname><given-names>SM</given-names></name><name><surname>Withrow</surname><given-names>SJ</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Wrigley</surname><given-names>RH</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Schwarz</surname><given-names>PD</given-names></name><etal></etal></person-group>. <article-title>Limb-sparing treatment for osteosarcoma in dogs</article-title>. <source>J Am Vet Med Assoc</source>. (<year>1989</year>) <volume>195</volume>:<fpage>1734</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">2599960</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Withrow</surname><given-names>SJ</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Straw</surname><given-names>RC</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Heidner</surname><given-names>GL</given-names></name><etal></etal></person-group>. <article-title>Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1990</year>) <volume>18</volume>:<fpage>1351</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(90)90308-7</pub-id><pub-id pub-id-type="pmid">2370184</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Withrow</surname><given-names>SJ</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Straw</surname><given-names>RC</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Wrigley</surname><given-names>RH</given-names></name><name><surname>Larue</surname><given-names>SM</given-names></name><etal></etal></person-group>. <article-title>Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma</article-title>. <source>Cancer</source>. (<year>1993</year>) <volume>71</volume>:<fpage>2484</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(19930415)71:8<2484::AID-CNCR2820710810>3.0.CO;2-D</pub-id><pub-id pub-id-type="pmid">8453572</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Withrow</surname><given-names>SJ</given-names></name><name><surname>Wilkins</surname><given-names>RM</given-names></name></person-group>. <article-title>Cross talk from pets to people: translational osteosarcoma treatments</article-title>. <source>ILAR J</source>. (<year>2010</year>) <volume>51</volume>:<fpage>208</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/ilar.51.3.208</pub-id><pub-id pub-id-type="pmid">21131721</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lascelles</surname><given-names>BD</given-names></name><name><surname>Dernell</surname><given-names>WS</given-names></name><name><surname>Correa</surname><given-names>MT</given-names></name><name><surname>Lafferty</surname><given-names>M</given-names></name><name><surname>Devitt</surname><given-names>CM</given-names></name><name><surname>Kuntz</surname><given-names>CA</given-names></name><etal></etal></person-group>. <article-title>Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma</article-title>. <source>Ann Surg Oncol</source>. (<year>2005</year>) <volume>12</volume>:<fpage>1073</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1245/ASO.2005.01.011</pub-id><pub-id pub-id-type="pmid">16252138</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeys</surname><given-names>LM</given-names></name><name><surname>Grimer</surname><given-names>RJ</given-names></name><name><surname>Carter</surname><given-names>SR</given-names></name><name><surname>Tillman</surname><given-names>RM</given-names></name><name><surname>Abudu</surname><given-names>A</given-names></name></person-group>. <article-title>Post operative infection and increased survival in osteosarcoma patients: are they associated?</article-title><source>Ann Surg Oncol</source>. (<year>2007</year>) <volume>14</volume>:<fpage>2887</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-007-9483-8</pub-id><pub-id pub-id-type="pmid">17653803</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sottnik</surname><given-names>JL</given-names></name><name><surname>U'Ren</surname><given-names>LW</given-names></name><name><surname>Thamm</surname><given-names>DH</given-names></name><name><surname>Withrow</surname><given-names>SJ</given-names></name><name><surname>Dow</surname><given-names>SW</given-names></name></person-group>. <article-title>Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2010</year>) <volume>59</volume>:<fpage>367</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-009-0755-y</pub-id><pub-id pub-id-type="pmid">19701748</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Maurer</surname><given-names>GD</given-names></name><name><surname>Severin</surname><given-names>GA</given-names></name></person-group>. <article-title>Endothelial repair of radiation damage following beta irradiation</article-title>. <source>Radiology</source>. (<year>1975</year>) <volume>116</volume>:<fpage>175</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1148/116.1.175</pub-id><pub-id pub-id-type="pmid">1138263</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fike</surname><given-names>JR</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Clow</surname><given-names>DJ</given-names></name></person-group>. <article-title>Repair of sublethal radiation damage by capillaries</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1979</year>) <volume>5</volume>:<fpage>339</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(79)91213-6</pub-id><pub-id pub-id-type="pmid">457479</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>PR</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name></person-group>. <article-title>Radiation response of the canine cardiovascular system</article-title>. <source>Radiat Res</source>. (<year>1982</year>) <volume>90</volume>:<fpage>489</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.2307/3575726</pub-id><pub-id pub-id-type="pmid">7089173</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Mcchesney</surname><given-names>SL</given-names></name><name><surname>Hoopes</surname><given-names>PJ</given-names></name></person-group>. <article-title>Isoeffect curves for radiation-induced cardiomyopathy in the dog</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1985</year>) <volume>11</volume>:<fpage>2091</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(85)90089-6</pub-id><pub-id pub-id-type="pmid">4066441</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoopes</surname><given-names>PJ</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Benjamin</surname><given-names>SA</given-names></name></person-group><article-title>The pathogenesis of radiation nephropathy in the dog</article-title>. <source>Radiat Res</source>. (<year>1985</year>) <volume>104</volume>:<fpage>406</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.2307/3576600</pub-id><pub-id pub-id-type="pmid">4080983</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Mcchesney</surname><given-names>SL</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name></person-group>. <article-title>Late radiation response of the canine trachea with change in dose per fraction</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1987</year>) <volume>13</volume>:<fpage>1673</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(87)90164-7</pub-id><pub-id pub-id-type="pmid">3667374</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadu-Suka</surname><given-names>F</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Withrow</surname><given-names>SJ</given-names></name><name><surname>Husted</surname><given-names>PW</given-names></name><name><surname>Nelson</surname><given-names>AW</given-names></name><name><surname>Whiteman</surname><given-names>CE</given-names></name></person-group>. <article-title>Exocrine pancreatic function following intraoperative irradiation of the canine pancreas</article-title>. <source>Cancer</source>. (<year>1988</year>) <volume>62</volume>:<fpage>1091</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(19880915)62:6<1091::AID-CNCR2820620611>3.0.CO;2-A</pub-id><pub-id pub-id-type="pmid">3409185</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ching</surname><given-names>SV</given-names></name><name><surname>Gillette</surname><given-names>SM</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Roberts</surname><given-names>SM</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Withrow</surname><given-names>SJ</given-names></name></person-group>. <article-title>Radiation-induced ocular injury in the dog: a histological study</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1990</year>) <volume>19</volume>:<fpage>321</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(90)90540-Z</pub-id><pub-id pub-id-type="pmid">2394611</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillette</surname><given-names>SM</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Orton</surname><given-names>EC</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name></person-group>. <article-title>Early radiation response of the canine heart and lung</article-title>. <source>Radiat Res</source>. (<year>1991</year>) <volume>125</volume>:<fpage>34</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.2307/3577979</pub-id><pub-id pub-id-type="pmid">1986399</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>BE</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Gillette</surname><given-names>SL</given-names></name><name><surname>Lecouteur</surname><given-names>RA</given-names></name><name><surname>Withrow</surname><given-names>SJ</given-names></name></person-group>. <article-title>Muscle injury following experimental intraoperative irradiation</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1991</year>) <volume>20</volume>:<fpage>463</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(91)90058-C</pub-id><pub-id pub-id-type="pmid">1995532</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillette</surname><given-names>SM</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name><etal></etal></person-group>. <article-title>Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: a randomized phase II study</article-title>. <source>Int J Hyperthermia</source>. (<year>1992</year>) <volume>8</volume>:<fpage>309</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.3109/02656739209021786</pub-id><pub-id pub-id-type="pmid">1607736</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McChesney</surname><given-names>SL</given-names></name><name><surname>Gillette</surname><given-names>EL</given-names></name><name><surname>Powers</surname><given-names>BE</given-names></name></person-group>. <article-title>Response of the canine lung to fractionated irradiation: pathologic changes and isoeffect curves</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1989</year>) <volume>16</volume>:<fpage>125</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(89)90019-9</pub-id><pub-id pub-id-type="pmid">2912933</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>TR</given-names></name><name><surname>Kapatoes</surname><given-names>J</given-names></name><name><surname>Ruchala</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Olivera</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Image guidance for precise conformal radiotherapy</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2003</year>) <volume>56</volume>:<fpage>89</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/S0360-3016(03)00090-7</pub-id><pub-id pub-id-type="pmid">12694827</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrest</surname><given-names>LJ</given-names></name><name><surname>Mackie</surname><given-names>TR</given-names></name><name><surname>Ruchala</surname><given-names>K</given-names></name><name><surname>Turek</surname><given-names>M</given-names></name><name><surname>Kapatoes</surname><given-names>J</given-names></name><name><surname>Jaradat</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2004</year>) <volume>60</volume>:<fpage>1639</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijrobp.2004.08.016</pub-id><pub-id pub-id-type="pmid">15590196</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Larue</surname><given-names>SM</given-names></name><name><surname>Pruitt</surname><given-names>AF</given-names></name><name><surname>Case</surname><given-names>B</given-names></name><name><surname>Dewhirst</surname><given-names>MW</given-names></name></person-group>. <article-title>Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas</article-title>. <source>Int J Hyperthermia</source>. (<year>2006</year>) <volume>22</volume>:<fpage>365</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1080/02656730600836386</pub-id><pub-id pub-id-type="pmid">16891239</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>JT</given-names></name><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Snyder</surname><given-names>S</given-names></name><name><surname>Fels</surname><given-names>D</given-names></name><name><surname>Landon</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics</article-title>. <source>Clin Cancer Res</source>. (<year>2011</year>) <volume>17</volume>:<fpage>2549</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2583</pub-id><pub-id pub-id-type="pmid">21292819</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrall</surname><given-names>DE</given-names></name><name><surname>Maccarini</surname><given-names>P</given-names></name><name><surname>Stauffer</surname><given-names>P</given-names></name><name><surname>Macfall</surname><given-names>J</given-names></name><name><surname>Hauck</surname><given-names>M</given-names></name><name><surname>Snyder</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Thermal dose fractionation affects tumour physiological response</article-title>. <source>Int J Hyperthermia</source>. (<year>2012</year>) <volume>28</volume>:<fpage>431</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3109/02656736.2012.689087</pub-id><pub-id pub-id-type="pmid">22804741</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hershey</surname><given-names>AE</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Forrest</surname><given-names>LJ</given-names></name><name><surname>Bohling</surname><given-names>CA</given-names></name><name><surname>Stonerook</surname><given-names>M</given-names></name><name><surname>Placke</surname><given-names>ME</given-names></name><etal></etal></person-group>. <article-title>Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model</article-title>. <source>Clin Cancer Res</source>. (<year>1999</year>) <volume>5</volume>:<fpage>2653</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">10499645</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>CO</given-names><suffix>Jr.</suffix></name><name><surname>Crabbs</surname><given-names>TA</given-names></name><name><surname>Wilson</surname><given-names>DW</given-names></name><name><surname>Cannan</surname><given-names>VA</given-names></name><name><surname>Skorupski</surname><given-names>KA</given-names></name><etal></etal></person-group>. <article-title>Aerosol gemcitabine: preclinical safety and <italic>in vivo</italic> antitumor activity in osteosarcoma-bearing dogs</article-title>. <source>J Aerosol Med Pulm Drug Deliv</source>. (<year>2010</year>) <volume>23</volume>:<fpage>197</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1089/jamp.2009.0773</pub-id><pub-id pub-id-type="pmid">19803732</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>PM</given-names></name><name><surname>Hasz</surname><given-names>DE</given-names></name><name><surname>Katsanis</surname><given-names>E</given-names></name><name><surname>Neville</surname><given-names>M</given-names></name><name><surname>Klausner</surname><given-names>JS</given-names></name></person-group>. <article-title>Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases</article-title>. <source>Cancer</source>. (<year>1997</year>) <volume>79</volume>:<fpage>1409</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19970401)79:7<1409::AID-CNCR19>3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">9083164</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>NJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Bai</surname><given-names>RY</given-names></name><name><surname>Staedtke</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses</article-title>. <source>Sci Transl Med</source>. (<year>2014</year>) <volume>6</volume>:<fpage>249ra111</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3008982</pub-id><pub-id pub-id-type="pmid">25122639</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dow</surname><given-names>SW</given-names></name><name><surname>Elmslie</surname><given-names>RE</given-names></name><name><surname>Willson</surname><given-names>AP</given-names></name><name><surname>Roche</surname><given-names>L</given-names></name><name><surname>Gorman</surname><given-names>C</given-names></name><name><surname>Potter</surname><given-names>TA</given-names></name></person-group>. <article-title><italic>In vivo</italic> tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma</article-title>. <source>J Clin Invest</source>. (<year>1998</year>) <volume>101</volume>:<fpage>2406</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1172/JCI510</pub-id><pub-id pub-id-type="pmid">9616212</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thamm</surname><given-names>DH</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Macewen</surname><given-names>EG</given-names></name><name><surname>Feinmehl</surname><given-names>R</given-names></name><name><surname>Towell</surname><given-names>TL</given-names></name><name><surname>Longhofer</surname><given-names>SL</given-names></name><etal></etal></person-group>. <article-title>Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2003</year>) <volume>52</volume>:<fpage>473</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-003-0387-6</pub-id><pub-id pub-id-type="pmid">12768328</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finocchiaro</surname><given-names>LM</given-names></name><name><surname>Villaverde</surname><given-names>MS</given-names></name><name><surname>Gil-Cardeza</surname><given-names>ML</given-names></name><name><surname>Riveros</surname><given-names>MD</given-names></name><name><surname>Glikin</surname><given-names>GC</given-names></name></person-group>. <article-title>Cytokine-enhanced vaccine and interferon-beta plus suicide gene as combined therapy for spontaneous canine sarcomas</article-title>. <source>Res Vet Sci</source>. (<year>2011</year>) <volume>91</volume>:<fpage>230</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.rvsc.2010.12.012</pub-id><pub-id pub-id-type="pmid">21300385</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westberg</surname><given-names>S</given-names></name><name><surname>Sadeghi</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>E</given-names></name><name><surname>Segall</surname><given-names>T</given-names></name><name><surname>Dimopoulou</surname><given-names>M</given-names></name><name><surname>Korsgren</surname><given-names>O</given-names></name><etal></etal></person-group>. <article-title>Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma</article-title>. <source>J Immunother</source>. (<year>2013</year>) <volume>36</volume>:<fpage>350</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/CJI.0b013e31829d8a1b</pub-id><pub-id pub-id-type="pmid">23799414</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theon</surname><given-names>AP</given-names></name><name><surname>Madewell</surname><given-names>BR</given-names></name><name><surname>Moore</surname><given-names>AS</given-names></name><name><surname>Stephens</surname><given-names>C</given-names></name><name><surname>Krag</surname><given-names>DN</given-names></name></person-group>. <article-title>Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours</article-title>. <source>Int J Hyperthermia</source>. (<year>1991</year>) <volume>7</volume>:<fpage>881</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.3109/02656739109056456</pub-id><pub-id pub-id-type="pmid">1806642</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitchell</surname><given-names>BE</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Luck</surname><given-names>EE</given-names></name><name><surname>Woods</surname><given-names>LL</given-names></name><name><surname>Orenberg</surname><given-names>EK</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name></person-group>. <article-title>Intralesional implant for treatment of primary oral malignant melanoma in dogs</article-title>. <source>J Am Vet Med Assoc</source>. (<year>1994</year>) <volume>204</volume>:<fpage>229</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">8144382</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theon</surname><given-names>AP</given-names></name><name><surname>Madewell</surname><given-names>BR</given-names></name><name><surname>Ryu</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>J</given-names></name></person-group>. <article-title>Concurrent irradiation and intratumoral chemotherapy with cisplatin: a pilot study in dogs with spontaneous tumors</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1994</year>) <volume>29</volume>:<fpage>1027</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/0360-3016(94)90398-0</pub-id><pub-id pub-id-type="pmid">8083071</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitchell</surname><given-names>BK</given-names></name><name><surname>Orenberg</surname><given-names>EK</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Hutson</surname><given-names>C</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name><name><surname>Woods</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma</article-title>. <source>Eur J Cancer</source>. (<year>1995</year>) <volume>31A</volume>:<fpage>2093</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0959-8049(95)00446-7</pub-id><pub-id pub-id-type="pmid">8562171</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venable</surname><given-names>RO</given-names></name><name><surname>Worley</surname><given-names>DR</given-names></name><name><surname>Gustafson</surname><given-names>DL</given-names></name><name><surname>Hansen</surname><given-names>RJ</given-names></name><name><surname>Ehrhart</surname><given-names>EJ</given-names><suffix>III</suffix></name><name><surname>Cai</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas</article-title>. <source>Am J Vet Res</source>. (<year>2012</year>) <volume>73</volume>:<fpage>1969</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.2460/ajvr.73.12.1969</pub-id><pub-id pub-id-type="pmid">23176425</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>CA</given-names></name><name><surname>Galli</surname><given-names>SJ</given-names></name><name><surname>Yuuki</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>ZQ</given-names></name><name><surname>Helfand</surname><given-names>SC</given-names></name><name><surname>Geissler</surname><given-names>EN</given-names></name></person-group>. <article-title>Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit</article-title>. <source>Exp Hematol</source>. (<year>1999</year>) <volume>27</volume>:<fpage>689</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/S0301-472X(98)00075-7</pub-id><pub-id pub-id-type="pmid">10210327</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>B</given-names></name><name><surname>Parker</surname><given-names>HG</given-names></name><name><surname>Dhawan</surname><given-names>D</given-names></name><name><surname>Kwon</surname><given-names>EM</given-names></name><name><surname>Karlins</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>BW</given-names></name><etal></etal></person-group>. <article-title>Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer–evidence for a relevant model system and urine-based diagnostic test</article-title>. <source>Mol Cancer Res</source>. (<year>2015</year>) <volume>13</volume>:<fpage>993</fpage>–<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0689</pub-id><pub-id pub-id-type="pmid">25767210</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochizuki</surname><given-names>H</given-names></name><name><surname>Breen</surname><given-names>M</given-names></name></person-group>. <article-title>Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma</article-title>. <source>Vet Comp Oncol</source>. (<year>2017</year>) <volume>15</volume>:<fpage>1598</fpage>–<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1111/vco.12275</pub-id><pub-id pub-id-type="pmid">27714944</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>AT</given-names></name><name><surname>Chien</surname><given-names>MB</given-names></name><name><surname>Shenoy</surname><given-names>N</given-names></name><name><surname>Mendel</surname><given-names>DB</given-names></name><name><surname>Mcmahon</surname><given-names>G</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors</article-title>. <source>Blood</source>. (<year>2002</year>) <volume>100</volume>:<fpage>585</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2001-12-0350</pub-id><pub-id pub-id-type="pmid">12091352</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>CA</given-names></name><name><surname>Hannah</surname><given-names>AL</given-names></name><name><surname>Zadovoskaya</surname><given-names>R</given-names></name><name><surname>Chien</surname><given-names>MB</given-names></name><name><surname>Kollias-Baker</surname><given-names>C</given-names></name><name><surname>Rosenberg</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies</article-title>. <source>Clin Cancer Res</source>. (<year>2003</year>) <volume>9</volume>:<fpage>2755</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">12855656</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pryer</surname><given-names>NK</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Zadovaskaya</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Sukbuntherng</surname><given-names>J</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors</article-title>. <source>Clin Cancer Res</source>. (<year>2003</year>) <volume>9</volume>:<fpage>5729</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">14654558</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>CA</given-names></name><name><surname>Malpas</surname><given-names>PB</given-names></name><name><surname>Wood-Follis</surname><given-names>SL</given-names></name><name><surname>Boucher</surname><given-names>JF</given-names></name><name><surname>Rusk</surname><given-names>AW</given-names></name><name><surname>Rosenberg</surname><given-names>MP</given-names></name><etal></etal></person-group>. <article-title>Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision</article-title>. <source>Clin Cancer Res</source>. (<year>2009</year>) <volume>15</volume>:<fpage>3856</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1860</pub-id><pub-id pub-id-type="pmid">19470739</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>CA</given-names></name><name><surname>Bernabe</surname><given-names>LF</given-names></name><name><surname>Barnard</surname><given-names>S</given-names></name><name><surname>Kisseberth</surname><given-names>WC</given-names></name><name><surname>Borgatti</surname><given-names>A</given-names></name><name><surname>Henson</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study</article-title>. <source>PLoS ONE</source>. (<year>2014</year>) <volume>9</volume>:<fpage>e87585</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0087585</pub-id><pub-id pub-id-type="pmid">24503695</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honigberg</surname><given-names>LA</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Sirisawad</surname><given-names>M</given-names></name><name><surname>Verner</surname><given-names>E</given-names></name><name><surname>Loury</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2010</year>) <volume>107</volume>:<fpage>13075</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1004594107</pub-id><pub-id pub-id-type="pmid">20615965</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoloni</surname><given-names>MC</given-names></name><name><surname>Tandle</surname><given-names>A</given-names></name><name><surname>Mazcko</surname><given-names>C</given-names></name><name><surname>Hanna</surname><given-names>E</given-names></name><name><surname>Kachala</surname><given-names>S</given-names></name><name><surname>Leblanc</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature</article-title>. <source>PLoS ONE</source>. (<year>2009</year>) <volume>4</volume>:<fpage>e4972</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0004972</pub-id><pub-id pub-id-type="pmid">19330034</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thamm</surname><given-names>DH</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>King</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>Dubielzig</surname><given-names>RR</given-names></name><etal></etal></person-group>. <article-title>Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation</article-title>. <source>Clin Cancer Res</source>. (<year>2005</year>) <volume>11</volume>:<fpage>4827</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2510</pub-id><pub-id pub-id-type="pmid">16000580</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toso</surname><given-names>JF</given-names></name><name><surname>Gill</surname><given-names>VJ</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Schwartzentruber</surname><given-names>DJ</given-names></name><etal></etal></person-group>. <article-title>Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma</article-title>. <source>J Clin Oncol</source>. (<year>2002</year>) <volume>20</volume>:<fpage>142</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.20.1.142</pub-id><pub-id pub-id-type="pmid">11773163</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauck</surname><given-names>ML</given-names></name><name><surname>Larue</surname><given-names>SM</given-names></name><name><surname>Petros</surname><given-names>WP</given-names></name><name><surname>Poulson</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Spasojevic</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors</article-title>. <source>Clin Cancer Res</source>. (<year>2006</year>) <volume>12</volume>:<fpage>4004</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0226</pub-id><pub-id pub-id-type="pmid">16818699</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>RA</given-names></name><name><surname>Wittenburg</surname><given-names>LA</given-names></name><name><surname>Amaravadi</surname><given-names>RK</given-names></name><name><surname>Gustafson</surname><given-names>DL</given-names></name><name><surname>Thorburn</surname><given-names>A</given-names></name><name><surname>Thamm</surname><given-names>DH</given-names></name></person-group>. <article-title>Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma</article-title>. <source>Autophagy</source>. (<year>2014</year>) <volume>10</volume>:<fpage>1415</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.4161/auto.29165</pub-id><pub-id pub-id-type="pmid">24991836</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>JH</given-names></name><name><surname>Mazcko</surname><given-names>C</given-names></name><name><surname>Leblanc</surname><given-names>A</given-names></name><name><surname>Covey</surname><given-names>JM</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Kinders</surname><given-names>RJ</given-names></name><etal></etal></person-group>. <article-title>NCI Comparative Oncology Program testing of non-camptothecin indenoisoquinoline topoisomerase i inhibitors in naturally occurring canine lymphoma</article-title>. <source>Clin Cancer Res</source>. (<year>2018</year>) <volume>24</volume>:<fpage>5830</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1498</pub-id><pub-id pub-id-type="pmid">30061364</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Macewen</surname><given-names>EG</given-names></name><name><surname>Rosenthal</surname><given-names>RC</given-names></name><name><surname>Fox</surname><given-names>LE</given-names></name><name><surname>Keller</surname><given-names>ET</given-names></name><name><surname>Helfand</surname><given-names>SC</given-names></name><etal></etal></person-group>. <article-title>Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin</article-title>. <source>Clin Cancer Res</source>. (<year>1995</year>) <volume>1</volume>:<fpage>1595</fpage>–<lpage>601</lpage>.<pub-id pub-id-type="pmid">9815961</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>Macewen</surname><given-names>EG</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Dubielzig</surname><given-names>RR</given-names></name><name><surname>Helfand</surname><given-names>SC</given-names></name><name><surname>Kisseberth</surname><given-names>WC</given-names></name><etal></etal></person-group>. <article-title>Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial</article-title>. <source>Clin Cancer Res</source>. (<year>1995</year>) <volume>1</volume>:<fpage>1165</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">9815908</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>Macewen</surname><given-names>EG</given-names></name></person-group>. <article-title><italic>In vitro</italic> and <italic>in vivo</italic> enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells</article-title>. <source>Cancer Biother Radiopharm</source>. (<year>1999</year>) <volume>14</volume>:<fpage>121</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1089/cbr.1999.14.121</pub-id><pub-id pub-id-type="pmid">10850295</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>PA</given-names></name><name><surname>Schwartz</surname><given-names>CL</given-names></name><name><surname>Krailo</surname><given-names>M</given-names></name><name><surname>Kleinerman</surname><given-names>ES</given-names></name><name><surname>Betcher</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>ML</given-names></name><etal></etal></person-group>. <article-title>Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate</article-title>. <source>J Clin Oncol</source>. (<year>2005</year>) <volume>23</volume>:<fpage>2004</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2005.06.031</pub-id><pub-id pub-id-type="pmid">15774791</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Glawe</surname><given-names>PC</given-names></name><name><surname>O'Brien</surname><given-names>MG</given-names></name><name><surname>Chun</surname><given-names>R</given-names></name><name><surname>Garrett</surname><given-names>LD</given-names></name><etal></etal></person-group>. <article-title>STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial</article-title>. <source>Cancer Chemother Pharmacol</source>. (<year>2002</year>) <volume>50</volume>:<fpage>131</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-002-0469-8</pub-id><pub-id pub-id-type="pmid">12172978</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgatti</surname><given-names>A</given-names></name><name><surname>Koopmeiners</surname><given-names>JS</given-names></name><name><surname>Sarver</surname><given-names>AL</given-names></name><name><surname>Winter</surname><given-names>AL</given-names></name><name><surname>Stuebner</surname><given-names>K</given-names></name><name><surname>Todhunter</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR</article-title>. <source>Mol Cancer Ther</source>. (<year>2017</year>) <volume>16</volume>:<fpage>956</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0637</pub-id><pub-id pub-id-type="pmid">28193671</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Horiuchi</surname><given-names>Y</given-names></name><name><surname>Nagasaki</surname><given-names>T</given-names></name><name><surname>Sakonju</surname><given-names>I</given-names></name><name><surname>Kakuta</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>U</given-names></name><etal></etal></person-group>. <article-title>Evaluation of immunological status in tumor-bearing dogs</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2009</year>) <volume>132</volume>:<fpage>85</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2009.04.020</pub-id><pub-id pub-id-type="pmid">19464737</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Andres</surname><given-names>PJ</given-names></name><name><surname>Illera</surname><given-names>JC</given-names></name><name><surname>Caceres</surname><given-names>S</given-names></name><name><surname>Diez</surname><given-names>L</given-names></name><name><surname>Perez-Alenza</surname><given-names>MD</given-names></name><name><surname>Pena</surname><given-names>L</given-names></name></person-group>. <article-title>Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2013</year>) <volume>152</volume>:<fpage>245</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2012.12.010</pub-id><pub-id pub-id-type="pmid">23351639</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Frantz</surname><given-names>AM</given-names></name><name><surname>Anderson</surname><given-names>KL</given-names></name><name><surname>Graef</surname><given-names>AJ</given-names></name><name><surname>Scott</surname><given-names>MC</given-names></name><name><surname>Robinson</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment</article-title>. <source>Exp Cell Res</source>. (<year>2014</year>) <volume>323</volume>:<fpage>155</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2014.02.020</pub-id><pub-id pub-id-type="pmid">24582862</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troyer</surname><given-names>RM</given-names></name><name><surname>Ruby</surname><given-names>CE</given-names></name><name><surname>Goodall</surname><given-names>CP</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Maier</surname><given-names>CS</given-names></name><name><surname>Albarqi</surname><given-names>HA</given-names></name><etal></etal></person-group>. <article-title>Exosomes from osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells</article-title>. <source>Exp Cell Res</source>. (<year>2017</year>) <volume>358</volume>:<fpage>369</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2017.07.011</pub-id><pub-id pub-id-type="pmid">28712929</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>BJ</given-names></name><name><surname>Elmslie</surname><given-names>RE</given-names></name><name><surname>Burnett</surname><given-names>RC</given-names></name><name><surname>Avery</surname><given-names>AC</given-names></name><name><surname>Dow</surname><given-names>SW</given-names></name></person-group>. <article-title>Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2007</year>) <volume>116</volume>:<fpage>69</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2006.12.002</pub-id><pub-id pub-id-type="pmid">17224188</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>K</given-names></name><name><surname>Guth</surname><given-names>A</given-names></name><name><surname>Biller</surname><given-names>B</given-names></name><name><surname>Elmslie</surname><given-names>R</given-names></name><name><surname>Dow</surname><given-names>S</given-names></name></person-group>. <article-title>Changes in regulatory T cells in dogs with cancer and associations with tumor type</article-title>. <source>J Vet Intern Med</source>. (<year>2009</year>) <volume>23</volume>:<fpage>875</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-1676.2009.0333.x</pub-id><pub-id pub-id-type="pmid">19496904</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>BJ</given-names></name><name><surname>Guth</surname><given-names>A</given-names></name><name><surname>Burton</surname><given-names>JH</given-names></name><name><surname>Dow</surname><given-names>SW</given-names></name></person-group>. <article-title>Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma</article-title>. <source>J Vet Intern Med</source>. (<year>2010</year>) <volume>24</volume>:<fpage>1118</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-1676.2010.0557.x</pub-id><pub-id pub-id-type="pmid">20666983</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goulart</surname><given-names>MR</given-names></name><name><surname>Pluhar</surname><given-names>GE</given-names></name><name><surname>Ohlfest</surname><given-names>JR</given-names></name></person-group>. <article-title>Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer</article-title>. <source>PLoS ONE</source>. (<year>2012</year>) <volume>7</volume>:<fpage>e33274</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0033274</pub-id><pub-id pub-id-type="pmid">22428007</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherger</surname><given-names>M</given-names></name><name><surname>Kisseberth</surname><given-names>W</given-names></name><name><surname>London</surname><given-names>C</given-names></name><name><surname>Olivo-Marston</surname><given-names>S</given-names></name><name><surname>Papenfuss</surname><given-names>TL</given-names></name></person-group>. <article-title>Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs</article-title>. <source>BMC Vet Res</source>. (<year>2012</year>) <volume>8</volume>:<fpage>209</fpage>. <pub-id pub-id-type="doi">10.1186/1746-6148-8-209</pub-id><pub-id pub-id-type="pmid">23110794</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goulart</surname><given-names>MR</given-names></name><name><surname>Hlavaty</surname><given-names>SI</given-names></name><name><surname>Chang</surname><given-names>YM</given-names></name><name><surname>Polton</surname><given-names>G</given-names></name><name><surname>Stell</surname><given-names>A</given-names></name><name><surname>Perry</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>:<fpage>3574</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-40285-3</pub-id><pub-id pub-id-type="pmid">30837603</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beirao</surname><given-names>BC</given-names></name><name><surname>Raposo</surname><given-names>T</given-names></name><name><surname>Pang</surname><given-names>LY</given-names></name><name><surname>Argyle</surname><given-names>DJ</given-names></name></person-group>. <article-title>Canine mammary cancer cells direct macrophages toward an intermediate activation state between M1/M2</article-title>. <source>BMC Vet Res</source>. (<year>2015</year>) <volume>11</volume>:<fpage>151</fpage>. <pub-id pub-id-type="doi">10.1186/s12917-015-0473-y</pub-id><pub-id pub-id-type="pmid">26174804</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>DP</given-names></name><name><surname>Escaffi</surname><given-names>A</given-names></name><name><surname>Coy</surname><given-names>J</given-names></name><name><surname>Kurihara</surname><given-names>J</given-names></name><name><surname>Dow</surname><given-names>SW</given-names></name></person-group>. <article-title>Role of monocyte recruitment in hemangiosarcoma metastasis in dogs</article-title>. <source>Vet Comp Oncol</source>. (<year>2017</year>) <volume>15</volume>:<fpage>1309</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/vco.12272</pub-id><pub-id pub-id-type="pmid">27779362</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname><given-names>LN</given-names></name><name><surname>Rodrigues</surname><given-names>MA</given-names></name><name><surname>Gomes</surname><given-names>DA</given-names></name><name><surname>Salgado</surname><given-names>BS</given-names></name><name><surname>Cassali</surname><given-names>GD</given-names></name></person-group>. <article-title>Tumour-associated macrophages: relation with progression and invasiveness, and assessment of M1/M2 macrophages in canine mammary tumours</article-title>. <source>Vet J</source>. (<year>2018</year>) <volume>234</volume>:<fpage>119</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.tvjl.2018.02.016</pub-id><pub-id pub-id-type="pmid">29680383</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seung</surname><given-names>BJ</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Shin</surname><given-names>JI</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><etal></etal></person-group>. <article-title>CD204-expressing tumor-associated macrophages are associated with malignant, high-grade, and hormone receptor-negative canine mammary gland tumors</article-title>. <source>Vet Pathol</source>. (<year>2018</year>) <volume>55</volume>:<fpage>417</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1177/0300985817750457</pub-id><pub-id pub-id-type="pmid">29343199</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname><given-names>N</given-names></name><name><surname>Konnai</surname><given-names>S</given-names></name><name><surname>Ikebuchi</surname><given-names>R</given-names></name><name><surname>Okagawa</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade</article-title>. <source>PLoS ONE</source>. (<year>2014</year>) <volume>9</volume>:<fpage>e98415</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0098415</pub-id><pub-id pub-id-type="pmid">24915569</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname><given-names>N</given-names></name><name><surname>Konnai</surname><given-names>S</given-names></name><name><surname>Okagawa</surname><given-names>T</given-names></name><name><surname>Nishimori</surname><given-names>A</given-names></name><name><surname>Ikebuchi</surname><given-names>R</given-names></name><name><surname>Izumi</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma</article-title>. <source>PLoS ONE</source>. (<year>2016</year>) <volume>11</volume>:<fpage>e0157176</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0157176</pub-id><pub-id pub-id-type="pmid">27276060</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosius</surname><given-names>LA</given-names></name><name><surname>Dhawan</surname><given-names>D</given-names></name><name><surname>Ramos-Vara</surname><given-names>JA</given-names></name><name><surname>Ruple</surname><given-names>A</given-names></name><name><surname>Knapp</surname><given-names>DW</given-names></name><name><surname>Childress</surname><given-names>MO</given-names></name></person-group>. <article-title>Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma</article-title>. <source>Am J Vet Res</source>. (<year>2018</year>) <volume>79</volume>:<fpage>643</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2460/ajvr.79.6.643</pub-id><pub-id pub-id-type="pmid">30085860</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartley</surname><given-names>G</given-names></name><name><surname>Elmslie</surname><given-names>R</given-names></name><name><surname>Dow</surname><given-names>S</given-names></name><name><surname>Guth</surname><given-names>A</given-names></name></person-group>. <article-title>Checkpoint molecule expression by B and T cell lymphomas in dogs</article-title>. <source>Vet Comp Oncol</source>. (<year>2018</year>) <volume>16</volume>:<fpage>352</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1111/vco.12386</pub-id><pub-id pub-id-type="pmid">29380929</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chand</surname><given-names>SK</given-names></name><name><surname>Pendharkar</surname><given-names>SA</given-names></name><name><surname>Bharmal</surname><given-names>SH</given-names></name><name><surname>Bartlett</surname><given-names>AS</given-names></name><name><surname>Pandol</surname><given-names>SJ</given-names></name><name><surname>Petrov</surname><given-names>MS</given-names></name></person-group>. <article-title>Frequency and risk factors for liver disease following pancreatitis: a population-based cohort study</article-title>. <source>Dig Liver Dis</source>. (<year>2019</year>) <volume>51</volume>:<fpage>551</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.dld.2018.11.001</pub-id><pub-id pub-id-type="pmid">30522894</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bech-Nielsen</surname><given-names>S</given-names></name><name><surname>Brodey</surname><given-names>RS</given-names></name><name><surname>Fidler</surname><given-names>IJ</given-names></name><name><surname>Abt</surname><given-names>DA</given-names></name><name><surname>Reif</surname><given-names>JS</given-names></name></person-group>. <article-title>The effect of BCG on <italic>in vitro</italic> immune reactivity and clinical course in dogs treated surgically for osteosarcoma</article-title>. <source>Eur J Cancer</source>. (<year>1977</year>) <volume>13</volume>:<fpage>33</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/0014-2964(77)90227-4</pub-id><pub-id pub-id-type="pmid">321227</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bostock</surname><given-names>DE</given-names></name><name><surname>Gorman</surname><given-names>NT</given-names></name></person-group>. <article-title>Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour</article-title>. <source>Eur J Cancer</source>. (<year>1978</year>) <volume>14</volume>:<fpage>879</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/0014-2964(78)90104-4</pub-id><pub-id pub-id-type="pmid">689057</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>JA</given-names></name><name><surname>Dueland</surname><given-names>RT</given-names></name><name><surname>Macewen</surname><given-names>EG</given-names></name><name><surname>Macy</surname><given-names>DW</given-names></name><name><surname>Hoefle</surname><given-names>WD</given-names></name><name><surname>Richardson</surname><given-names>RC</given-names></name><etal></etal></person-group>. <article-title>Canine osteogenic sarcoma treated by amputation and MER: an adverse effect of splenectomy on survival</article-title>. <source>Cancer</source>. (<year>1982</year>) <volume>49</volume>:<fpage>1613</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(19820415)49:8<1613::AID-CNCR2820490814>3.0.CO;2-R</pub-id><pub-id pub-id-type="pmid">6950801</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>AL</given-names></name><name><surname>Misdorp</surname><given-names>W</given-names></name><name><surname>Mialot</surname><given-names>JP</given-names></name><name><surname>Mialot</surname><given-names>M</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Hurtrel</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy</article-title>. <source>Cancer Immunol Immunother</source>. (<year>1983</year>) <volume>15</volume>:<fpage>172</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/BF00199160</pub-id><pub-id pub-id-type="pmid">6555059</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>CJ</given-names></name><name><surname>Downing</surname><given-names>S</given-names></name><name><surname>Rosenthal</surname><given-names>RC</given-names></name><name><surname>Klein</surname><given-names>MK</given-names></name><name><surname>Meleo</surname><given-names>K</given-names></name><name><surname>Villamil</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs</article-title>. <source>Am J Vet Res</source>. (<year>2007</year>) <volume>68</volume>:<fpage>1246</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2460/ajvr.68.11.1246</pub-id><pub-id pub-id-type="pmid">17975981</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macewen</surname><given-names>EG</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Vail</surname><given-names>DM</given-names></name><name><surname>Dubielzig</surname><given-names>RR</given-names></name><name><surname>Everlith</surname><given-names>K</given-names></name><name><surname>Madewell</surname><given-names>BR</given-names></name><etal></etal></person-group>. <article-title>Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor</article-title>. <source>Clin Cancer Res</source>. (<year>1999</year>) <volume>5</volume>:<fpage>4249</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">10632367</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>AS</given-names></name><name><surname>Theilen</surname><given-names>GH</given-names></name><name><surname>Newell</surname><given-names>AD</given-names></name><name><surname>Madewell</surname><given-names>BR</given-names></name><name><surname>Rudolf</surname><given-names>AR</given-names></name></person-group>. <article-title>Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms</article-title>. <source>Cancer Res</source>. (<year>1991</year>) <volume>51</volume>:<fpage>233</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">1899040</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mito</surname><given-names>K</given-names></name><name><surname>Sugiura</surname><given-names>K</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Hori</surname><given-names>T</given-names></name><name><surname>Akazawa</surname><given-names>T</given-names></name><name><surname>Yamate</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>IFNγ markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models</article-title>. <source>Cancer Res</source>. (<year>2010</year>) <volume>70</volume>:<fpage>7093</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0600</pub-id><pub-id pub-id-type="pmid">20823157</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henson</surname><given-names>MS</given-names></name><name><surname>Curtsinger</surname><given-names>JM</given-names></name><name><surname>Larson</surname><given-names>VS</given-names></name><name><surname>Klausner</surname><given-names>JS</given-names></name><name><surname>Modiano</surname><given-names>JF</given-names></name><name><surname>Mescher</surname><given-names>MF</given-names></name><etal></etal></person-group>. <article-title>Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma</article-title>. <source>Vet Comp Oncol</source>. (<year>2011</year>) <volume>9</volume>:<fpage>95</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5829.2010.00234.x</pub-id><pub-id pub-id-type="pmid">21569195</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konietschke</surname><given-names>U</given-names></name><name><surname>Teske</surname><given-names>E</given-names></name><name><surname>Jurina</surname><given-names>K</given-names></name><name><surname>Stockhaus</surname><given-names>C</given-names></name></person-group>. <article-title>Palliative intralesional interleukin-2 treatment in dogs with urinary bladder and urethral carcinomas</article-title>. <source>In Vivo</source>. (<year>2012</year>) <volume>26</volume>:<fpage>931</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">23160674</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagsman</surname><given-names>AN</given-names></name><name><surname>Witkamp</surname><given-names>AC</given-names></name><name><surname>Sjollema</surname><given-names>BE</given-names></name><name><surname>Kik</surname><given-names>MJ</given-names></name><name><surname>Kirpensteijn</surname><given-names>J</given-names></name></person-group>. <article-title>The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study</article-title>. <source>BMC Vet Res</source>. (<year>2013</year>) <volume>9</volume>:<fpage>155</fpage>. <pub-id pub-id-type="doi">10.1186/1746-6148-9-155</pub-id><pub-id pub-id-type="pmid">23927575</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziekman</surname><given-names>PG</given-names></name><name><surname>Otter</surname><given-names>WD</given-names></name><name><surname>Tan</surname><given-names>JF</given-names></name><name><surname>Teske</surname><given-names>E</given-names></name><name><surname>Kirpensteijn</surname><given-names>J</given-names></name><name><surname>Koten</surname><given-names>JW</given-names></name><etal></etal></person-group>. <article-title>Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs</article-title>. <source>Anticancer Res</source>.(<year>2013</year>) <volume>33</volume>:<fpage>161</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">23267141</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finocchiaro</surname><given-names>LM</given-names></name><name><surname>Fondello</surname><given-names>C</given-names></name><name><surname>Gil-Cardeza</surname><given-names>ML</given-names></name><name><surname>Rossi</surname><given-names>UA</given-names></name><name><surname>Villaverde</surname><given-names>MS</given-names></name><name><surname>Riveros</surname><given-names>MD</given-names></name><etal></etal></person-group>. <article-title>Cytokine-enhanced vaccine and interferon-beta plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma</article-title>. <source>Hum Gene Ther</source>. (<year>2015</year>) <volume>26</volume>:<fpage>367</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2014.130</pub-id><pub-id pub-id-type="pmid">25762364</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monjazeb</surname><given-names>AM</given-names></name><name><surname>Kent</surname><given-names>MS</given-names></name><name><surname>Grossenbacher</surname><given-names>SK</given-names></name><name><surname>Mall</surname><given-names>C</given-names></name><name><surname>Zamora</surname><given-names>AE</given-names></name><name><surname>Mirsoian</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies</article-title>. <source>Clin Cancer Res</source>. (<year>2016</year>) <volume>22</volume>:<fpage>4328</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-3026</pub-id><pub-id pub-id-type="pmid">26979392</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicchelero</surname><given-names>L</given-names></name><name><surname>Denies</surname><given-names>S</given-names></name><name><surname>Haers</surname><given-names>H</given-names></name><name><surname>Vanderperren</surname><given-names>K</given-names></name><name><surname>Stock</surname><given-names>E</given-names></name><name><surname>Van Brantegem</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer</article-title>. <source>Vet Comp Oncol</source>. (<year>2017</year>) <volume>15</volume>:<fpage>1187</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1111/vco.12255</pub-id><pub-id pub-id-type="pmid">27506827</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoloni</surname><given-names>M</given-names></name><name><surname>Mazcko</surname><given-names>C</given-names></name><name><surname>Selting</surname><given-names>K</given-names></name><name><surname>Lana</surname><given-names>S</given-names></name><name><surname>Barber</surname><given-names>L</given-names></name><name><surname>Phillips</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma</article-title>. <source>PLoS ONE</source>. (<year>2015</year>) <volume>10</volume>:<fpage>e0129954</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0129954</pub-id><pub-id pub-id-type="pmid">26091536</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>CA</given-names></name><name><surname>Gardner</surname><given-names>HL</given-names></name><name><surname>Rippy</surname><given-names>S</given-names></name><name><surname>Post</surname><given-names>G</given-names></name><name><surname>La Perle</surname><given-names>K</given-names></name><name><surname>Crew</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells</article-title>. <source>Clin Cancer Res</source>. (<year>2017</year>) <volume>23</volume>:<fpage>2565</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2152</pub-id><pub-id pub-id-type="pmid">27815356</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname><given-names>N</given-names></name><name><surname>Konnai</surname><given-names>S</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Kagawa</surname><given-names>Y</given-names></name><name><surname>Okagawa</surname><given-names>T</given-names></name><name><surname>Nishimori</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>8951</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-09444-2</pub-id><pub-id pub-id-type="pmid">28827658</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogge</surname><given-names>GS</given-names></name><name><surname>Burkholder</surname><given-names>JK</given-names></name><name><surname>Culp</surname><given-names>J</given-names></name><name><surname>Albertini</surname><given-names>MR</given-names></name><name><surname>Dubielzig</surname><given-names>RR</given-names></name><name><surname>Keller</surname><given-names>ET</given-names></name><etal></etal></person-group>. <article-title>Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer</article-title>. <source>Hum Gene Ther</source>. (<year>1998</year>) <volume>9</volume>:<fpage>1851</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1089/hum.1998.9.13-1851</pub-id><pub-id pub-id-type="pmid">9741424</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turek</surname><given-names>MM</given-names></name><name><surname>Thamm</surname><given-names>DH</given-names></name><name><surname>Mitzey</surname><given-names>A</given-names></name><name><surname>Kurzman</surname><given-names>ID</given-names></name><name><surname>Huelsmeyer</surname><given-names>MK</given-names></name><name><surname>Dubielzig</surname><given-names>RR</given-names></name><etal></etal></person-group>. <article-title>Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma</article-title>. <source>Vet Comp Oncol</source>. (<year>2007</year>) <volume>5</volume>:<fpage>219</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5829.2007.00128.x</pub-id><pub-id pub-id-type="pmid">19754780</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>RC</given-names></name><name><surname>Deinnocentes</surname><given-names>P</given-names></name><name><surname>Church Bird</surname><given-names>AE</given-names></name><name><surname>Van Ginkel</surname><given-names>FW</given-names></name><name><surname>Lindquist</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>BF</given-names></name></person-group>. <article-title>An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2011</year>) <volume>60</volume>:<fpage>87</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-010-0921-2</pub-id><pub-id pub-id-type="pmid">21069323</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorenmo</surname><given-names>KU</given-names></name><name><surname>Krick</surname><given-names>E</given-names></name><name><surname>Coughlin</surname><given-names>CM</given-names></name><name><surname>Overley</surname><given-names>B</given-names></name><name><surname>Gregor</surname><given-names>TP</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><etal></etal></person-group>. <article-title>CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma</article-title>. <source>PLoS ONE</source>. (<year>2011</year>) <volume>6</volume>:<fpage>e24167</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024167</pub-id><pub-id pub-id-type="pmid">21904611</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marconato</surname><given-names>L</given-names></name><name><surname>Frayssinet</surname><given-names>P</given-names></name><name><surname>Rouquet</surname><given-names>N</given-names></name><name><surname>Comazzi</surname><given-names>S</given-names></name><name><surname>Leone</surname><given-names>VF</given-names></name><name><surname>Laganga</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma</article-title>. <source>Clin Cancer Res</source>. (<year>2014</year>) <volume>20</volume>:<fpage>668</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2283</pub-id><pub-id pub-id-type="pmid">24300788</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>U'Ren</surname><given-names>LW</given-names></name><name><surname>Biller</surname><given-names>BJ</given-names></name><name><surname>Elmslie</surname><given-names>RE</given-names></name><name><surname>Thamm</surname><given-names>DH</given-names></name><name><surname>Dow</surname><given-names>SW</given-names></name></person-group>. <article-title>Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma</article-title>. <source>J Vet Intern Med</source>. (<year>2007</year>) <volume>21</volume>:<fpage>113</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-1676.2007.tb02936.x</pub-id><pub-id pub-id-type="pmid">17338158</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>PJ</given-names></name><name><surname>Mcknight</surname><given-names>J</given-names></name><name><surname>Novosad</surname><given-names>A</given-names></name><name><surname>Charney</surname><given-names>S</given-names></name><name><surname>Farrelly</surname><given-names>J</given-names></name><name><surname>Craft</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial</article-title>. <source>Clin Cancer Res</source>. (<year>2003</year>) <volume>9</volume>:<fpage>1284</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">12684396</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>PJ</given-names></name><name><surname>Camps-Palau</surname><given-names>MA</given-names></name><name><surname>Mcknight</surname><given-names>JA</given-names></name><name><surname>Leibman</surname><given-names>NF</given-names></name><name><surname>Craft</surname><given-names>DM</given-names></name><name><surname>Leung</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center</article-title>. <source>Vaccine</source>. (<year>2006</year>) <volume>24</volume>:<fpage>4582</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.027</pub-id><pub-id pub-id-type="pmid">16188351</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamstock</surname><given-names>D</given-names></name><name><surname>Elmslie</surname><given-names>R</given-names></name><name><surname>Thamm</surname><given-names>D</given-names></name><name><surname>Dow</surname><given-names>S</given-names></name></person-group>. <article-title>Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2007</year>) <volume>56</volume>:<fpage>1299</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-007-0282-7</pub-id><pub-id pub-id-type="pmid">17502972</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavazza</surname><given-names>A</given-names></name><name><surname>Lubas</surname><given-names>G</given-names></name><name><surname>Fridman</surname><given-names>A</given-names></name><name><surname>Peruzzi</surname><given-names>D</given-names></name><name><surname>Impellizeri</surname><given-names>JA</given-names></name><name><surname>Luberto</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma</article-title>. <source>Hum Gene Ther</source>. (<year>2013</year>) <volume>24</volume>:<fpage>728</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2013.112</pub-id><pub-id pub-id-type="pmid">23902422</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>NJ</given-names></name><name><surname>Gnanandarajah</surname><given-names>JS</given-names></name><name><surname>Engiles</surname><given-names>JB</given-names></name><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Laughlin</surname><given-names>D</given-names></name><name><surname>Gaurnier-Hausser</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma</article-title>. <source>Clin Cancer Res</source>. (<year>2016</year>) <volume>22</volume>:<fpage>4380</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-0088</pub-id><pub-id pub-id-type="pmid">26994144</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mie</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Akiyoshi</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>A</given-names></name><name><surname>Ohashi</surname><given-names>F</given-names></name></person-group>. <article-title>Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection</article-title>. <source>Vet Immunol Immunopathol</source>. (<year>2016</year>) <volume>177</volume>:<fpage>58</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2016.06.007</pub-id><pub-id pub-id-type="pmid">27436446</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>CM</given-names></name><name><surname>Sheppard</surname><given-names>S</given-names></name><name><surname>Hartline</surname><given-names>CA</given-names></name><name><surname>Huls</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Palla</surname><given-names>SL</given-names></name><etal></etal></person-group>. <article-title>Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy</article-title>. <source>Sci Rep</source>. (<year>2012</year>) <volume>2</volume>:<fpage>249</fpage>. <pub-id pub-id-type="doi">10.1038/srep00249</pub-id><pub-id pub-id-type="pmid">22355761</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>CC</given-names></name><name><surname>Igase</surname><given-names>M</given-names></name><name><surname>Sakurai</surname><given-names>M</given-names></name><name><surname>Haraguchi</surname><given-names>T</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Itamoto</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Oncolytic reovirus therapy: pilot study in dogs with spontaneously occurring tumours</article-title>. <source>Vet Comp Oncol</source>. (<year>2018</year>) <volume>16</volume>:<fpage>229</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1111/vco.12361</pub-id><pub-id pub-id-type="pmid">29076241</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>S</given-names></name><name><surname>Galyon</surname><given-names>GD</given-names></name><name><surname>Jenks</surname><given-names>NJ</given-names></name><name><surname>Steele</surname><given-names>MB</given-names></name><name><surname>Miller</surname><given-names>AC</given-names></name><name><surname>Allstadt</surname><given-names>SD</given-names></name><etal></etal></person-group>. <article-title>Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer</article-title>. <source>Mol Cancer Ther</source>. (<year>2018</year>) <volume>17</volume>:<fpage>316</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0432</pub-id><pub-id pub-id-type="pmid">29158470</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panjwani</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>JB</given-names></name><name><surname>Schutsky</surname><given-names>K</given-names></name><name><surname>Gnanandarajah</surname><given-names>J</given-names></name><name><surname>O'Connor</surname><given-names>CM</given-names></name><name><surname>Powell</surname><given-names>DJ</given-names></name><etal></etal></person-group>. <article-title>Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B Cell lymphoma</article-title>. <source>Mol Ther</source>. (<year>2016</year>) <volume>24</volume>:<fpage>1602</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2016.146</pub-id><pub-id pub-id-type="pmid">27401141</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Dow</surname><given-names>S</given-names></name><name><surname>Elmslie</surname><given-names>R</given-names></name><name><surname>Potter</surname><given-names>T</given-names></name><name><surname>Glode</surname><given-names>LM</given-names></name><etal></etal></person-group>. <article-title>A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma</article-title>. <source>Univ Colorado Cancer Center Clinical Trial Hum Gene Ther</source>. (<year>2000</year>) <volume>11</volume>:<fpage>1355</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1089/10430340050032447</pub-id><pub-id pub-id-type="pmid">10890744</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Ku</surname><given-names>GY</given-names></name><name><surname>Adamow</surname><given-names>M</given-names></name><name><surname>Mu</surname><given-names>Z</given-names></name><name><surname>Tandon</surname><given-names>S</given-names></name><name><surname>Hannaman</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma</article-title>. <source>J Immunother Cancer</source>. (<year>2013</year>) <volume>1</volume>:<fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/2051-1426-1-20</pub-id><pub-id pub-id-type="pmid">24829756</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000986 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000986 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6873901
|texte= Canine Cancer: Strategies in Experimental Therapeutics
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31803625" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |